Your SlideShare is downloading. ×
berekcv2006.doc
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

berekcv2006.doc

1,172
views

Published on


0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,172
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CURRICULUM VITAE 1/2006 Jonathan S. Berek, MD, MMS Professor and Chair Department of Obstetrics and Gynecology Stanford University School of Medicine Chief of Obstetrics and Gynecology Stanford University Hospital and Clinics Group Chair Cooperative Ovarian Cancer Group for Immunotherapy (COGI) OFFICE Department of Obstetrics and Gynecology Stanford University School of Medicine 300 Pasteur Drive, HH-333 Stanford, California 94305-5317 (650) 723-5533 Phone (650) 723-7737 Fax e-mail jberek@stanford.edu
  • 2. Jonathan S. Berek, MD, MMS EDUCATION AND TRAINING SECONDARY SCHOOL Fremont Senior High School Fremont, NE Diploma 1966 UNIVERSITY A.B., Brown University Providence, RI 1970 English & American Literature Theatre Arts & Dramatic Literature M.M.S., Brown University 1973 Biomedical Sciences MEDICAL SCHOOL M.D., Johns Hopkins University School of Medicine 1975 Baltimore, MD INTERNSHIP Harvard Medical School Boston, MA 1975-76 Departments of Obstetrics & Gynecology and Surgery Peter Bent Brigham Hospital Boston Hospital for Women Brigham and Women's Hospital Surgery 1975 Obstetrics & Gynecology 1975-76 RESIDENCY Harvard Medical School Boston, MA 1976-79 Department of Obstetrics and Gynecology Boston Hospital for Women Brigham and Women's Hospital Resident in Obstetrics & Gynecology 1976-78 Administrative Chief Resident 1978-79 FELLOWSHIP UCLA School of Medicine 1979-81 University of California, Los Angeles Division of Gynecologic Oncology Fellow in Gynecologic Oncology UCLA Medical Center Cedars-Sinai Medical Center City of Hope National Medical Center 2
  • 3. Jonathan S. Berek, MD, MMS APPOINTMENTS AND POSITIONS ACADEMIC APPOINTMENTS Professor Stanford University School of Medicine 2006- Professor VIII David Geffen School of Medicine at UCLA 2004-5 Professor VII David Geffen School of Medicine at UCLA 2002-4 Professor VI UCLA School of Medicine 2000-2 Professor UCLA School of Medicine 1989-2000 Associate Professor UCLA School of Medicine 1984-89 Tenure 1984 Assistant Professor UCLA School of Medicine 1981-84 Clinical Instructor UCLA School of Medicine 1979-81 Clinical Fellow Harvard Medical School 1975-79 POSITIONS Stanford University Hospital and Clinics Chief Obstetrics and Gynecology 2005- Universitry of California at Los Angeles Chair UCLA Medical Institution Review Board I 2005 David Geffen School of Medicine at UCLA Chair College of Applied Anatomy 2000-5 Executive Vice Chair Department of Obstetrics and Gynecology 2002-5 Vice Chair Department of Obstetrics and Gynecology 1991-2002 Chief of Gynecology Department of Obstetrics and Gynecology 2002-5 Chief Division of Gynecologic Oncology Department of Obstetrics and Gynecology 19862005- Chief Division of Gynecology 1988-97 Department of Obstetrics and Gynecology Director Gynecologic Oncology Service 1986-2005 Division of Gynecologic Oncology 3
  • 4. Jonathan S. Berek, MD, MMS Department of Obstetrics and Gynecology Director UCLA Women’s Reproductive Cancer Program 1996-2005 Chair Sherman M. Mellinkoff Faculty Award Committee 2002-2003 Director Rhonda Fleming Women's Clinic 1991-93 Department of Obstetrics and Gynecology Director Program Area in Gynecologic Oncology 1986-96 UCLA Jonsson Comprehensive Cancer Center Director UCLA Women's Reproductive Cancer Program Jonsson Comprehensive Cancer Center 1996-2005 Director Residency Program Department of Obstetrics & Gynecology 1996-2000 Chief of Staff UCLA Medical Center 1996-98 Vice Chief of Staff 1994-96 Secretary 1992-94 Director Fellowship Program, Gynecologic Oncology Department of Obstetrics and Gynecology 1986-98 Associate Director Division Gynecologic Oncology 1985-86 Department of Obstetrics and Gynecology Medical Director 2-East Intensive Care Unit 1983-89 POSITIONS (OTHER) Group Chair Cooperative Ovarian Cancer Group for Immunotherapy (COGI) 2004- Principal Investigator Examiner American Board Obstetrics & Gynecology 1991- Associate Examiner 1989-91 Examiner Council on Resident Education in 1990-9 Obstetrics and Gynecology (CREOG) Committee on In-Training Examination for Residents in Obstetrics and Gynecology HONORS Sherman Mellinkoff Faculty Award 2004 David Geffen School of Medicine at UCLA Excellence in Education Award 2003 David Geffen School of Medicine at UCLA Excellence in Teaching Award 2003, 2004 Department of Obstetrics and Gynecology 1995,97, 1985,87 President's Award 4
  • 5. Jonathan S. Berek, MD, MMS Society of Gynecologic Oncologists 1987 Vice President Society of Gynecologic Oncologists 1996-97 America's Best Doctors Gynecology & Gynecologic Oncology 1992-2005 America’s Top Doctors for Cancer Gynecologic Oncology 2004 National Faculty Award Council on Residency Education in Obstetrics & Gynecology 1997 America's 400 Best Cancer Specialists Good Housekeeping Magazine 1990,97 Best 2000 Doctors Gynecologic Oncology American Health 1996, 2001 The Best Doctors in America 1992-2004 The Best Doctors in America: Pacific Region 1996-2003 America’s Top Doctors 2001-4 Twenty-First Century Award for Achievement 2003 Who’s Who in Science and Engineering 2004- Who's Who in the West 1989- Who's Who in America 1993- Who's Who in the World 1994- American Men and Women of Science 1993- Men of Achievement 1994- Bethesda II Committee National Institutes of Health 1991-92 Bethesda III Committee National Institutes of Health 2001-92 President Western Association of Gynecologic Oncologists 1991 Administrative Chief Resident, Obstetrics & Gynecology Harvard Medical School 1978-79 Phi Beta Kappa Johns Hopkins University School of Medicine 1975 Alpha Omega Alpha Johns Hopkins University School of Medicine 1975 Graduation with Honors Johns Hopkins University School of Medicine 1975 Koennecke Award in Gynecology Johns Hopkins University School of Medicine 1975 Sigma XI Brown University 1972 Graduation cum laude Brown University 1970 William S. Cherry, Jr. Scholar Brown University 1967-70 Dean's List Brown University 1967-70 American Field Service Scholarship 1965-66 DISTINGUISHED LECTURESHIPS 5
  • 6. Jonathan S. Berek, MD, MMS Baker-Channing Society Lecturer 1989, Harvard Medical School 1992 Symposium Lecturer, Ovarian Cancer 1991,93,95,97 Helene Harris Memorial Trust 1999,2001,03 New York Obstetrical Society Lecturer Yale Club 1993 Conrad Collins Distinguished Lecturer Tulane University School of Medicine 1994 Richard TeLinde Lecturer Johns Hopkins University School of Medicine 1995 Zeneca Lecturer British Gynaecological Cancer Society 1996 Saul Gusberg Distinguished Lecturer Mt. Sinai School of Medicine 1996 Frank R. Lock Lecturer Bowman Gray School of Medicine 1996 John Thompson Lecturer Emory University School of Medicine 1998 Shirley Nissen Lectureship Orange County Obstetrics and Gynecology Society 1998 University of California Irvine School of Medicine Visiting Professor Brown University School of Medicine 2000 International Distinguished Scholar and Lecturer Clinical Oncology Society of Australia 2000 International Examiner and Lecturer Australia and New Zealand Gynecological Oncology Board 2000 Asbury Memorial Lecturer Oregon State University School of Medicine 2001 Invited Lecturer Obstetrical Society of Boston 2001 International Guest Lecturer Finnish Oncology Society 2001 Distinguished Guest Lecturer Harvard Medical School, Beth Israel Deaconess 2002 Scholar in Gynecologic Cancer Harvard Medical School 2002 Cohen Lecturer New York State, North Shore University School of Medicine 2003 Distinuished Guest Lecturer Norwegian National Oncology Society 2003 EDITORIAL, STUDY REVIEWS & COMMITTEES SENIOR EDITOR International Journal of Gynecologic Cancer 2001- EDITOR Current Opinion in Obstetrics and Gynecology 2003- ASCO News 2004- 6
  • 7. Jonathan S. Berek, MD, MMS Precis, Gynecologic Oncology and Surgery 2003- Prolog, Gynecologic Oncology and Gynecology 2000- Journal of Gynecologic Techniques 1994-2000 EDITORIAL BOARDS Women’sHhealth Encyclopedia, ACOG 2004- Postgraduate Obstetrics and Gynecology 2002- Journal of Clinical Oncology 1998-2001 UpToDate, Gynecologic Oncology 1999- Gynecologic Oncology 1988-98 Clinical Progress in Obstetrics, Gynecology and Fertility 1988-96 Oncology Times 1990-96 International Journal of Gynecological Cancer 1990-2001 Journal of the Society for Gynecologic Investigation 1994- CME Journal of Gynecologic Oncology 1995- MANUSCRIPT REVIEWER Obstetrics & Gynecology 1981- American Journal of Obstetrics and Gynecology 1982- New England Journal of Medicine 1987- Cancer 1991- Cancer Treatment Reports, National Cancer Institute 1985-89 Journal of the National Cancer Institute 1989- Gynecologic Oncology 1985- Cancer Research 1986- Journal of Clinical Oncology 1987- Lippincott Williams and Wilkins, Publishers 1981- Cancer Update 1983-86 European Journal of Cancer and Clinical Oncology 1986- International Journal of Obstetrics & Gynecology 1996- Journal of the American Medical Association 1993- Journal of Clinical Oncology 1993- The Lancet 1994- The Cancer Journal 1999- HOSPITAL APPOINTMENTS Attending in Gynecologic Oncology 1981- Department of Obstetrics and Gynecology UCLA Medical Center Consultant in Gynecologic Oncology Cedars-Sinai Medical Center 1981- Olive View Medical Center 1983- Kaiser Permanente Medical Center 1980-90 Santa Monica/UCLA Medical Center 1984- St. John's Hospital 1987-99 Harbor/UCLA Medical Center 1988- Assistant Attending Surgeon 1979 Division of Gynecologic Oncology Department of Surgery 7
  • 8. Jonathan S. Berek, MD, MMS City of Hope National Medical Center Duarte, California CERTIFICATION AND LICENSURE BOARDS National Board of Medical Examiners, Diplomate 1976 American Board of Obstetrics and Gynecology Board Certified 1982 Recertified 1991, 2001 Subspecialty Certification in Gynecologic Oncology Board Certified 1983, 2001 LICENSURE The State of California, No. G39480 1979- The Commonwealth of Massachusetts, No. 39855 1976-79 Drug Enforcement Administration, AB884517 1976- CERTIFICATION UCLA John E. Anderson Graduate School of Management Program in Executive Management 1990 American Heart Association, Advanced Cardiac Life Support 1983 State of California Department of Health Services X-ray Supervisor and Operator 1996-2004 GRANT REVIEWER National Cancer Institute Immunology Program Project Ad Hoc Study Section 2004-5 Ovarian Cancer Study Group 1997-8 Ovarian Cancer Screening Study Group 1990-1 Representative to Board of Scientific Advisors 1990 Ovarian Cancer Research Committee 1990 Clinical Cancer Programs Review Committee 1985-6 Department of Defense Ovarian Cancer Research Program Ad Hoc Study Section 2004- Ovarian Cancer Research Fund Ovarian Cancer Grants 1999- WellBeing/RCOG Research Grants 1998- CONSULTANT/SCIENTIFIC ADVISOR Unither Pharmaceuticals, Scientific Advisor 2002- Cancer Education Consortium, Scientific Advisory Board, Vice Chair 2002- ABC News, Scientific Advisor 2002- Washington Post, Scientific Consultant 2002- 8
  • 9. Jonathan S. Berek, MD, MMS Wall Street Journal, Scientific Consultant 2002- Cardinal Health Foundation, Scientific Advisor 2002- Foundation for Better Health, Scientific Advisor 2002- National Medical Communications and Research, Consultant 2001- iKnowMed, Consultant 2001- Curry Rockefeller Group, LLC, Medical Advisory Board 2001- MDExpert, Scientific Advisor 2001- The Wellness Community, Medical Advisor 2001- Asociated Press, International, Scientific Consultant 2001- United Press International, Scientific Consultant 2001- Watson Pharmaceuticals, Scientific Advisory Board 2001- Altarex Pharmaceuticals, Scientific Advisor 2000- Intermune Pharmaceuticals, Scientific Advisor 2000-2 Ovarian Cancer Research Fund, Scientific Advisory Board 1999- Lippincott Williams and Wilkins, Publishers, Consultant 1998- GlaxoSmithKline Pharmaceuticals, Scientific Advisory Board 1998- SmithKline Beecham Pharmaceuticals, Scientific Advisory Board 1995-98 Stressgen Pharmaceuticals, Scientific Advisor 1998-2000 LA Times, Scientific Consultant 1994- Center for Biomedical Communications, Consultant 1993- Berlex Oncology, Scientific Advisory Board 1993-2002 William and Wilkins, Publisher, Consultant 1990-98 Schering Plough Pharmaceuticals, Scientific Advisor 1983-89 MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES American College of Obstetricians and Gynecologists Fellow 1983- Patient Education Committee, Member 1990-8 Chair 1995-8 Gynecologic Practice Committee, Member 1996- Prolog, Gynecologic Oncology & Surgery, Co-Chair 1998-2000 Women’s Health Encyclopedia, Editorial Board 2000-1 Gynecology Practice Bulletins, Member 1998-2001 Precis, Gynecologic Oncology, Editor 2001- American College of Surgeons Fellow 1984- American Gynecological & Obstetrical Society Fellow 1994- Society for Gynecologic Investigation, Member 1984- Program Committee 1987,94- Society for Gynecologic Oncologists 1984- Vice President 1996-7 Officer, Council Member 1993-6 Program Committee 1987,93 Chair 1997-98 Bylaws Committee 1989-93 Chair 1991-93 Medical Informatics Committee 1998-2000 International Committee 1994-99 9
  • 10. Jonathan S. Berek, MD, MMS International Gynecologic Cancer Society Officer & Council Member 1996-2000 Member 1987- Program Committee 1989- International Conference Chair 2006 2000- The Society of Brigham Surgical Alumni Harvard Medical School 1979- Baker Channing Society Harvard Medical School 1979- American Association for Cancer Education 2003- European Society of Gynecological Oncology 2003- American Medical Association CME Advisory Board/ACOG Representative 2003- Wellness Community National Advisor 2002- Ovarian Cancer Database Project Scientific Advisory Committee 2001- Ovarian Cancer National Alliance Scientific Advisory Coimmittee 2000- Western Association of Gynecologic Oncologists President 1991-92 Chair, Program Committee 1990-91 Program Committee 1989-90 Executive Committee 1988-95 Member 1982- American Board of Obstetrics and Gynecology Associate Examiner 1989-91 Examiner 1991- Council on Resident Education in Obstetrics and Gynecology Committee on In-Training Examination for Residents in Obstetrics and Gynecology Examiner 1990-98 National Cancer Institute, Clinical Cancer Programs Ovarian Cancer Study Group 1997 Review Committees 1985- Ovarian Cancer Screening Study Group 1990 Representative to Board of Scientific Advisors 1990 Ovarian Cancer Research Committee 1990 National Cancer Institute Immunology Program Project Ad Hoc Study Section 2004-5 Bethesda System II Committee, Member 1991-2 Bethesda System III Committee, Member 2001-2 ASCUS Committee, Member 2001 American Society of Cytopathology and Colposcopy Committee ACOG representative 2001 Gynecologic Oncology Group Principal Investigator 1986- Co-Investigator 1981-86 Immunology Committee Member 1982-84 Biologic Response Modifier Subcommittee 1984-90 10
  • 11. Jonathan S. Berek, MD, MMS Basic Science Committee 1990-93 Ovarian Committee Member 1984-96 Medical Oncology Committee 1985-93 Intraperitoneal Therapy Subcommittee Chair 1986-95 Phase I Studies Committee 1990-97 Quality of Life Committee 2000- American Society of Clinical Oncology Member 1983- Program Committee 1990, 99 Chair 2000 Patient Advocacy Committee 1991-92 Cancer Education Committee 1995-00 American Association for Cancer Research Member 1984- European Organization for the Research and Treatment of Cancer (EORTC) Consultant Member, GOG Representative 1987- Southwest Oncology Group (SWOG) Consultant Member 1986- Society of Surgical Oncologists Member 1985- Association of Professors of Gynecology and Obstetrics Member 1984- American Radium Society, Member 1984- Scientific Program Committee 1985-86 Membership Committee 1985-86 Officer, Council Member 1994-98 Resident Awards Committee 1996-98 Chair 1998 Planned Parenthood of America National Medical Committee Vice Chair 1989-91 Member 1985-91 Chair, Oncology Committee 1987-91 Vice Chair, Oncology Committee 1985-87 Southern California Academy of Clinical Oncology Member 1985- Daniel Morton Society 1984- Los Angeles Obstetrical and Gynecological Society Associate Member 1985-89 Fellow 1989- Johns Hopkins Medical and Surgical Association 1976- American College of Obstetricians & Gynecologists Chair, District I Junior Fellows 1977-78 Vice-Chair 1976-77 Johns Hopkins Medical Student Society, Executive Council Senior Class Representative 1974-75 March of Dimes, Medical Advisory Council Johns Hopkins Student Representative 1974-75 Brown University Medical Curriculum Committee Student Representative 1971-73 Venice Family Medical Clinic 11
  • 12. Jonathan S. Berek, MD, MMS UCLA Obstet Gynecol Faculty Liaison 1990-93 Volunteer 1995- CLINICAL RESEARCH STUDY GROUPS Bethesda System Committee, Member 1991-92 National Cancer Institute Gynecologic Oncology Group Principal Investigator 1986-2005 Co-Investigator 1981-86 Immunology Committee 1982-84 Biologic Response Modifier Committee 1984-90 Basic Science Committee 1990-94 Applied Sciences & Basic Biology Committee 1995-99 Ovarian Committee 1984-94 Medical Oncology Committee 1985-93 Chair, Intraperitoneal Therapy Committee 1986-94 Phase I Studies Committee 1990-98 Developmental Therapeutics Committee 1993-95 COMMITTEES Five-year Review Committee for Departmental Chair 2003 Ad hoc Promotion Committees for Academic Personnel 2002 Accreditation, Licensing and Policy Committee Chair 1994-96 Ad Hoc Committee on Out-patient Surgery 1985 Ad Hoc Committee on Residency Transfer Policy 1985 Ad Hoc Committee on Strategic Planning 1990 Ambulatory Surgery Committee 200 Medical Plaza 1991-93 Bowyer Oncology Clinic Acute Care Committee 1983-90 Tissue Committee 1983-85 Solid Tumor Study Group 1983-87 Clinical Programs Committee 1981-88 Chair 1987-93 Committee on Patient Education 1990-95 Chair 1993-95 Committee on Clinical Research 1999-2000 Credentials and Ethics Committee At Large Representative 1988 Department of Obstetrics and Gynecology Executive Committee 2002-5 Resident Education Committee 1983-86 Chair 1990-98 Committee on Residency 1981-90 Chair 12
  • 13. Jonathan S. Berek, MD, MMS Practice Plan Committee 1990-2005 Chair 90-2,96-8 Resident Education Committee 1981- Chair 1990- Resident Selection Committee 1981-87 Chair 84-86,97- 2005 Executive Policy Committee 1986-90 Fund Raising Committee 1982-83 Hospital Accreditation Executive Committee Chair 1994-95 Hospital Accreditation, Licensing and Policies Committee Chair 1994-96 Jonsson Comprehensive Cancer Center 1981 Clinical Programs Committee - Chair 1988-93 Executive Committee 1986-92 Subcommittees: Ambulatory Care Committee 200 Medical Plaza 1991-93 Medical Student Education Committee 1983-85 OR Task Force Chair 1994-95 Patient Care Committee 1981-83 Quality Assurance Executive Committee Chair 1994-96 Quality Improvement Executive Committee Chair 1996-98 Search Committee, Chairman Joint Appointment - UCLA School of Medicine & School of Public Health 1995-98 Chief of Obstetrics 1994 Chair of Radiation Oncology 1993-94 Steering Committee, Operations Excellence 1992-94 Transfusion Education Committee 1987-88 UCLA Academic Health Center - Westwood Campus Replacement Hospital: Functional & Space Programming Phase II Women’s Services/Steering Committee 1997-98 UCLA Hospital Asepsis Committee 1981-83 Operating Room Committee 1998-2003 OR Executive Committee 1998-2003 Cancer Committee Chair 1988-93 Member 2001-2 Executive Committee 1988-98 Medical Records Committee 1985-86 UCLA Medical Enterprise Managed Care and Contracting Executive Committee 2003-4 Faculty Practiice Group Operations and Finance Committee 2003-4 13
  • 14. Jonathan S. Berek, MD, MMS Clinical Effectiveness Committee - UCLA Medical Enterprise Chair 1998-2000 Clinical Effectiveness Initiative, Master Planning II Chair 1997-98 Executive Committee 1996 Finance Committee 1994 Liability Task Force Modularity and Standards Committee 1997-98 Steering Committee UCLA Master Planning II 1997-98 UCLA Medical Group Finance Committee 1994-96 At Large Member 2000- UCLA Medical Staff Executive Committee At Large Representative 1988-92 Secretary 1992-94 Hospital Liaison Committee - Chair 1992-94 Medical Staff Council 1990 Vice Chief of Staff 1994-96 Chief of Staff 1996-98 UCLA School of Medicine Clinical Studies Grant Review Committee Committee on the Size of the Medical School Co-Chair 1992-93 Curriculum Working Group 1991-93 Oncology Core Curriculum Medical School Task Force on Education 1992-93 Chair 1989-90 UCLA Healthcare Board Member 2001-3 UCLA/Harbor Obstetrics and Gynecology Chair Review, Chair 2001-2 RESEARCH GRANTS 1. National Cancer Institute, CA-13630, Gynecologic Oncology Group. Principal Investigator, 1986-1993. $450,000 2. California Institute for Cancer Research: Utilization of the murine ovarian tumor model to determine optimal dose and schedule of intraperitoneal chemotherapy. Principal Investigator, 1981-1982, $24,800 3. California Institute for Cancer Research: Evaluation of intraperitoneal chemotherapy in gynecologic oncology. Co-Principal Investigattor 1981-1982, $25,000 4. California Institute for Cancer Research: Intraperitoneal Corynebacterium parvum in ovarian cancer limited to the peritoneal cavity: a phase I toxicology and immunopharmacology study. Principal Investigator, 1982-1983, $25,000 14
  • 15. Jonathan S. Berek, MD, MMS 5. Romona Moskovitz Memorial Ovarian Cancer Research Foundation: Intraperitoneal chemotherapy and immunotherapy in murine ovarian cancer. Principal Investigator, 1982-1983, $50,000 6. PHS/National Cancer Institute: Nuclear DNA and morphometric studies of gynecologic cancers; Co-principal investigator, 1982-1989, $584,378 7. Centacor: Prospective study of monoclonal antibody (OC-125) in the blood of patients with adenocarcinoma of the female genital tract. Principal Investigator, 1983-1984, $72,500 8. Schering Corporation: Toxicology-immunopharmacology study of intraperitoneally administered human recombinant alpha2 interferon (Sch 30500) in ovarian cancer. Principal Investigator, 1983-1984, $48,000 9. National Cancer Institute: Immunobiology of the peritoneal cavity in ovarian cancer. Co-Principal Investigator, 1983-1986, $687,000 10. Schering Corporation: Randomized trial of topical recombinant alpha2-interferon in cervical dysplasia, 1985-1986, Principal Investigator, $54,000 11. The June Hill Fund: Intraperitoneal administration of chemo-immunotherapy in a murine ovarian cancer model. Principal Investigator, 1985-1986, $10,000 12. Dianon Corporation: Tumor markers in ovarian cancer. Principal Investigator, 1985-1987, $20,000 13. Upjohn Pharmaceuticals: The intraperitoneal administration of chemotherapy in a murine ovarian cancer model. Principal Investigator, 1985-1986, $32,000 14. National Cancer Institute: Behavior among women with abnormal Pap smears. Co-Principal Investigator, 1983-1985, Principal Investigator, 1986-87, $985,475 15. Schering Corporation: Phase I trial of the intraperitoneal administration of cisplatin plus alpha2-interferon in ovarian cancer. Principal Investigator, 1986-1987, $52,000 16. National Cancer Institute: Compliance Adherence in Women with Abnormal Pap Smears, Co-principal investigator, l986-l989, $658,940 17. National Cancer Institute: Improving Adherence Behavior among low income women with abnormal pap smears. USPHS CA 43461, Principal Investigator, 1988-1993, $1,236,450 18. National Cancer Institute: Psychosocial and sexual function of women with preinvasive vulvar cancer, Co-investigator, 1988-89, $423,890 19. California Institute for Cancer Research: Analysis of tumor susceptibility and immunologic changes in TNF (tumor necrosis factor)-treated ovarian cancer patients, Principal Investigator, 1988-89, $29,878 20. NeoRx: Intraperitoneal monoclonal antibody administration of Rhenium-186 labeled-antibody in ovarian cancer, Principal Investigator, 1989-91, $72,970 21. Ramona Moskovitz Memorial Cancer Research Fund: Ovarian cancer: immunobiology and molecular biological research, Principal Investigator, 1989-95, $60,000 15
  • 16. Jonathan S. Berek, MD, MMS 22. California Institute for Cancer Research: Ovarian Cancer-Produced Interleukin 6 (IL-6): Role in Tumor Development and Growth and Effects on Host Immune Function, Co-Principal Investigator, 1990-91, $29,860 23. Organon: ORG 2677 to prevent cisplatin-induced neuropathy in patients treated with combination chemotherapy for ovarian cancer. Principal Investigator, 1990-1992, $92,568 24. June Hill Fund: Investigation of interleukin-6 in ovarian cancer. Principal Investigator, 1990-93, $30,000 25. The Ted Mann Foundation, Rhonda Fleming Mann Program for Women's Comprehensive Care, Psychosocial function and intervention in gynecologic cancers, Principal Investigator, 1991-92, $385,000 26. National Institutes of Health, National Cancer Institute, CA-16042-18, UCLA Jonsson Comprehensive Cancer Center, Cancer Center Core Support Grant, Gynecologic Oncology Section, Co-investigator, 1991-95, $18,835 27. National Cancer Institute: Gynecologic Oncology Group. In vivo growth model for ovarian cancer and interleukin-6. Co-Principal investigator, 1991-92, $12,500 28. SmithKline Pharmacaeuticals, 930697-00-A04, Double-blind parallel multicenter study comparing the efficacy and safety of intravenous ganisetron, Co-investigator, 1992-96, $17,000 29. Jonsson Cancer Center Research Grant: Apoptosis and ovarian cancer. Faculty Principal investigator, 1994-96, $29,700 30. National Cancer Institute, CA-13630, A90-03368C-00, Gynecologic Oncology Group, Principal Investigator, 1994-2005, $600,000 31. American Cancer Society: Mechanisms of cytokine-mediated inhibition of apoptosis in ovarian cancer. Co-Principal Investigator, 1995-97, $196,000 32. Nicole Kidman/Tom Cruise Endowment, Women's Reproductive Cancer Treatment and Research Program, 1995-indef , $1,050,000 33. Viagene Corporation: Gene therapy in ovarian cancer using interleukin-2 transduced autologous tumor cells. Principal Investigator, 1996-97, $50,000. 34. SmithKline Pharmaceuticals. An open-label evaluation of topotecan administered intravenously as five daily 30 minute infusions every 21 days to patients with solid tumors refractory to other therapies, Principal investigator, 1996-7. 35. Anthra Pharmaceuticals. Phase III randomized study of intraperitoneal AD 32 (N- trifluoroacetyladriamycin-14-valerate) versus altretamine in ovarian cancer patients who have failed platinum and paclitaxel chemotherapy, Co-Principal Investigator, 1996-indef, $98,000 36. Vical, Phase I trial of intraperitoneal autologous vaccine with IL-2 gene transfected allogeneic ovarian cancer cells in residual ovarian cancer patients, Principal Investigator, $57,000. 37. Jennifer Jones Simon Foundation. Jennifer Jones Simon, Women’s Cancer Research. Principal Investigator - 1997-2001 - $200,000 16
  • 17. Jonathan S. Berek, MD, MMS 38. Antisoma. Multicenter randomized survival study of monoclonal antibody radioimmunotherapy: A multinational study in patients with ovarian carcinoma using HMFG1 antibody labeled with 90 Yttrium. Principal Investigator – 12/9/99- Indefinite, $29,400 39. AltaRex. A double-blind placebo controlled trial of intravenous ovarex MAb-B43.13 as post chemotherapy consolidation for ovarian tubal and peritoneal carcinoma. Principal Investigator – 07/24/00-07/23/2004, $55,750. 40. Dinah Shore Foundation. Ovarian Cancer Research, 1998-2000, $20,000. 41. Department of Health and Human Services, Division of Cancer Treatment, R01CA79750-A101- A telomerase assay for ovarian cancer detection. Co-investigator (PI= Louis Dubeau), 1999- 2004; $1,405,157 42. California Research Council, Gene-dietary interactions, Principal Investigator, 2000-2, $720,000 43. Berlex Foundation, Communications in Oncology, Principal Investigator, 2001-4, $330,000 44. Nancy Stolkin Vreeland Ovarian Cancer Fund. Princiapl Investigator. $45,000, 1/02-12/05 45. Muriel Lipsey Cancer Research Fund. Principal Investigator. $50,000, 1/02-12/05 46. Ovarian Cancer Database Foundation. Improving the process of therapeutic choice for ovarian cancer patients. Co-investigator, Santa Barbara, CA, 2003- 47. Seattle Genetics. A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with gemcitabine versus single agent gemcitabine in patients with advanced ovarian cancer. Principal Investigator, $134,237, 2003-5. 48. Intermune Pharmaceuticals. Actimune (Interferon gamma-1b) in combination with chemotherapy for first-line therapy of advanced ovarian or primary peritoneal carcinoma. Principal Investigator. $52,200, 9/25/02-9/24/03. 49. Unither. A double-blind, placebo-controlled multicenter clinical trial of intravenous OvaRex MAb- B43.13 as post chemotherapy consolidation for epithelial ovarian, tubal and peritoneal carcinoma. Principal Investigator, $75,000, 1/1/03-12/31/2004. 50. National Cancer Institute. Development of a curriculum for cancer as a chronic disease. Co- Investigator, $75,440, (PI=LuAnn Wilkerson), 7/1/02-6/30/07. 51. GlaxoSmithKline. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Principal Investigator, $18,000, 11/13/02-11/13/03. 52. National Cancer Institute, CA-13630, A90-03368C-00, Gynecologic Oncology Group, Principal Investigator, 2000-2005, $280,000 53. Ovarian Cancer Research Foundation, Program Project Grant, Cooperative Ovarian Cancer Group for Immunotherapy (COGI), Principal Investigator and Group Chair, 2005-8, $900,000 17
  • 18. Jonathan S. Berek, MD, MMS PUBLICATIONS Thesis, Reviewed 1. Berek, JS. The sex dependence of the physiological response to and the metabolism of aldosterone, in adrenalectomized, gonadectomized and intact rats. Thesis. Division of Biological and Medical Sciences, Brown University, May, 1973. Journal Publications, Peer reviewed 2. Morris DJ, Berek JS, David RP. The physiological response to aldosterone in adrenalectomized and intact rats and its sex dependence. Endocrinology 1973;92:989-993. 3. Morris DJ, Berek JS, Davis RP. Sex dependence of the metabolism of aldosterone in adrenalectomized and intact rats. Steroids 1973;21:397-407. 4. Morris DJ, Berek JS, Davis RP. Sex dependence of aldosterone response in rats. Metabolism 1973;22:923-926. 5. Garcia-Bunuel R, Berek JS, Woodruff JD. Luteomas of pregnancy. Obstet Gynecol 1975;45:407-414. 6. Garcia-Bunuel R, Berek JS, Woodruff JD Luteomas of pregnancy. Review. Obstet Gynecol Survey 1975;30:635-637. 7. Berek JS, Darney PD, Lopkin C, Goldstein DP. Avoiding ureteral damage in pelvic surgery for ovarian remnant syndrome. Am J Obstet Gynecol 1979;133:221-222. 8. Berek JS, Darney PD. Massive exudative ascites produced from a tubal pseudocyst in chronic pelvic inflammatory disease. Obstet Gynecol 1979;54:490-492. 9. Berek JS, Stubblefield PG. Anatomic and clinical correlates of uterine perforation. Am J Obstet Gynecol 1979;135:181-184. 10. Stubblefield PG, Frederiksen MC, Berek JS, Gatter MA, Kayman DJ, Borton M. Evaluation of a balloon dilator before second-trimester abortion by vacuum curettage. Am J Obstet Gynecol 1979;135:199-201. 11. Stubblefield PG, Berek JS. Perinatal mortality in term and post-term births. Obstet Gynecol 1980;56:676-682. 12. Berek JS, Griffiths CT, Leventhal JM. Laparoscopy for second-look evaluation in ovarian cancer. Obstet Gynecol 1981;58:192-198. 13. Hacker NF, Leuchter RS, Berek JS, Castaldo TW, Lagasse LD. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstet Gynecol 1981;58:574-579. 14. Berek JS, Castaldo TW, Hacker NF, Petrilli ES, Lagasse LD, Moore JG. Adenocarcinoma of the uterine cervix. Cancer 1981;48:2734-2741. 15. Hacker NF, Berek JS, Lagasse LD, Charles EH, Savage EW, Moore JG. Carcinoma of the cervix associated with pregnancy. Obstet Gynecol 1982;59:735-746. 18
  • 19. Jonathan S. Berek, MD, MMS 16. Berek JS, Lagasse LD, Hacker NF, Leuchter RS. Levator ani transposition for anal incompetence secondary to sphincter damage. Obstet Gynecol 1982;59:108-112. 17. Berek JS, Hacker NF, Lagasse LD, Leuchter RS. Lower urinary tract resection as part of cytoreductive surgery for ovarian cancer. Gynecol Oncol 1982;13:87-92. 18. Leuchter RS, Lagasse LD, Hacker NF, Berek JS. Management of postexenteration perineal hernias by myocutaneous axial flaps. Gynecol Oncol 1982;14:15-22. 19. Leuchter RS, Hacker NF, Voit R, Berek JS, Lagasse LD. Primary carcinoma of the Bartholin gland: a report of 14 cases and review of the literature. Obstet Gynecol 1982;60:361-368. 20. Berek JS, Hacker NF, Lagasse LD. Recent progress in the treatment of epithelial ovarian malignancy. West J Med 1982;137:273-277. 21. Berek JS, Castaldo TW, Hacker NF, Petrilli ES, Lagasse LD, Moore JG. Adenocarcinomas of the uterine cervix. Obstet Gynecol Survey 1982;37:348-349. 22. Berek JS, Hacker NF. Laparoscopy in the management of patients with ovarian cancer. Clin Obstet Gynaecol 1983;10(2):213-222. 23. Hacker NF, Nieberg RK, Berek JS, Leuchter RS, Lucas WE, Tamimi HK, Nolan JF, Moore JG, Lagasse LD. Superficially invasive vulvar cancer with nodal metastases. Gynecol Oncol 1983;15:65-77. 24. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins Y, Esmailian F, Leuchter RS, Delange RJ. Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol 1983;15:299-304. 25. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-193. 26. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-420. 27. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins YL, DeLange R. Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina and vulva. Gynecol Oncol 1983;15:27-31. 28. Berek JS, Hacker NF, Lagasse LD, Smith ML. Delayed vaginal reconstruction in the fibrotic pelvis following radiation or previous reconstruction. Obstet Gynecol 1983;61:743-748. 29. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium Parvum. Cancer Research 1983;43:1395-1401. 30. Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 1983;61:408-414. 31. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treatment Reports 1983;67:1085-1092. 32. Berek JS, Hacker NF, Lagasse LD. Vaginal reconstruction performed simultaneously with pelvic 19
  • 20. Jonathan S. Berek, MD, MMS exenteration. Obstet Gynecol 1984;63:318-323. 33. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 1984;63:155-162. 34. Hacker NF, Berek JS, Juillard GJF, Lagasse LD. Preoperative radiation therapy for locally advanced vulvar cancer. Cancer 1984;54:2056-2061. 35. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 1984;64:708-714. 36. Lichtenstein A, Berek JS, Bast RC, Spina C, Hacker NF, Knapp RC, Zighelboim J. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biologic Resp Mod. 1984;3(4):371-378. 37. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol 1984;64:207-212. 38. Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Nieberg RK, Poth T, Elashoff RM, Lagasse LD, Zighelboim J. Immunotherapy with biochemically dissociated fractions of Proprionibacterium acnes in a murine ovarian cancer model. Cancer Research 1984;44:1871-1875. 39. Lichtenstein A, Kahle J, Berek JS, Zighelboim J. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity. J Immunol 1984;133(1):519-526. 40. Berek JS, Hacker NF, Lagasse LD. Rectosigmoid colectomy and reanastamosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol 1984;64:715-720. 41. Lichtenstein AK, Berek JS, Kahle J, Zighelboim J. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice. Cancer Research 1984;44:5118-5123. 42. Berek JS. Vaginal reconstruction. Med Aspects Human Sexuality 12:21-6, 1984. 43. Berek JS, Hacker NF, Fu YS, Sokale JR, Leuchter RS, Lagasse LD. Adenocarcinoma of the uterine cervix: Histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 1985;65:46-52. 44. Lichtenstein AK, Berek JS, Zighelboim J. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. J Natl Cancer Inst 1985;74(2):349-55. 45. Hacker NF, Berek JS, Burnison CM, Heintz APM, Juillard GJF, Lagasse LD. Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 1985;65:60-66. 46. Berek JS, Lichtenstein AK, Knox RM, Jung TS, Rose TP, Cantrell JL, Zighelboim J. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Cancer Research 1985;45:4215-4218. 47. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz 20
  • 21. Jonathan S. Berek, MD, MMS RS, Parker L, Zighelboim J, Bast RC. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 1985;152:1003-1010. 48. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel R, Zighelboim J. Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Research 45:4447-4453, 1985; Seminars in Oncology 1985;13:61-71, 49. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ, Zighelboim J. Intraperitoneal recombinant α2-interferon for "salvage" immunotherapy in persistent epithelial ovarian cancer. Cancer Treatment Reviews 1985;12(Suppl B):23-32 (condensed and revised from 44). 50. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986;67:685-698. 51. Thigpen JT, Blessing JA, Homesley HD, Berek JS, Creasman WT. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group study. Gynecol Oncol 1986;23:101-104. 52. Heintz APM, Hacker NF, Berek JS, Rose T, Munoz AK, Lagasse LD Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-788. 53. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986;155:56-60. 54. Fu YS, Ro J, Reagan JW, Hall TL, Berek JS. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors. Obstet Gynecol 1986;67:478-482. 55. Smotkin D, Berek JS, Fu YS, Hacker NF, Major FJ, Wettstein F. Human papillomavirus deoxyribonuleic acid in adenocarcinoma and adenosquamous carcinomas of the uterine cervix. Obstet Gynecol 1986;68:241-244. 56. Lichtenstein A, Berek JS. Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes. Cancer Immunol Immunother 1986;22:24-30. 57. Cochran SD, Hacker NF, Berek JS. Correlates of delay in seeking treatment for endometrial cancer. J Psychosom Obstet Gynaecol 1986;5:245-252. 58. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JS, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987;69:223-227. 59. Cochran SD, Hacker NF, Wellisch DK, Berek JS. Sexual functioning after treatment for endometrial cancer. J Psychosocial Oncol 1987,5(2):47-61. 60. Hacker NF, Berek JS, Pretorius GR, Zuckerman J, Eisenkop S, Lagasse LD. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer. Obstet Gynecol 1987;70:759-764. 61. Fu YS, Hall TL, Berek JS, Hacker NF, Reagan JW. Prognostic significance of DNA ploidy and morphometric analyses of adenocarcinoma of the uterine cervix. Analytical Quantitative Cytol 21
  • 22. Jonathan S. Berek, MD, MMS Histol 1987;9:17-24. 62. Fu YS, Berek JS, Hilborne LH. Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Applied Pathology 1987;5:47-56. 63. Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S. Distant metastases in epithelial ovarian cancer. Cancer 1987;60:1561-1566. 64. Brand E, Berek JS, Nieberg RK, Hacker NF. Rhabdomyosarcoma of the uterine cervix: sarcoma botryoides. Cancer 1987;60:1552-1560. 65. Montz FJ, Berek JS. Treatment modalities that preserve sexual function in patients with gynecologic malignancy. Clin Prac Sexuality 1988;4:21-29. 66. Fu YS, Berek JS. Minimal cervical cancer: definition and histology. Rec Res Cancer Research 1988;106:47-56. 67. Zighelboim J, Nio Y, Berek JS, Bonavida B. Immunologic control of ovarian cancer. Nat Immun Cell Growth Regul 1988;7:216-225. 68. Brand E, Berek JS, Hacker NF. Controversies in the management of cervical adenocarcinoma. Obstet Gynecol 1988;71:261-269. 69. Berek JS, Hatch K, Hacker NF, Young RC. Uterine corpus and uterine cancer. Curr Prob Cancer 1988;12:65-129. 70. Nio Y, Zighelboim J, Berek JS, Bonavida B. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha2 , and OK-432. Cancer Immunol Immunother 1988;27:246-254. 71. Lichtenstein A, Spina C, Berek JS, Jung T, Zighelboim J. Intraperitoneal administration of human recombinant interferon-α in patients with ovarian cancer: effects on lymphocytes, phenotype and cytotoxicity. Cancer Research 1988;48:5853-5859. 72. Malkasian, Jr. GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast, Jr. RC, Ritts RY. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159(2):341-346. 73. Sagae S, Berek JS, Fu YS, Chang N, Dauplat J, Hacker NF. Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response. Obstet Gynecol 1988;72:782-788. 74. Eisner RF, Nieberg RK, Berek JS. Synchronous primary neoplasms of the female reproductive tract. Gynecol Oncol 1989;33:335-339. 75. Pretorius RG, Eisenkop S, Berek JS, Hacker NF, Ashikaga T, Knox RM. Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Gynecol Oncol 1989;34:66-69. 76. Berek JS, Schink JS, Knox RM. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. Obstet Gynecol 1989;74:663-666. 22
  • 23. Jonathan S. Berek, MD, MMS 77. Boyer PJ, Berek JS, Zighelboim J. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Obstet Gynecol 1989;73:793-797. 78. Brand E, Fu YS, Lagasse LD, Berek JS. Vulvovaginal melanoma: report of seven cases and literature review. Gynecol Oncol 1989;33:54-60. 79. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:457-465. 80. Nio Y, Zighelboim J, Berek JS, Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and it subcellular fractions on human ovarian tumor cells. Cancer 1989;64:434-441. 81. Montz FJ, Schlaerth J, Berek JS. Resection of diaphragmatic peritoneum and muscle: Role in cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1989;35:338-340. 82. Montz FJ, Berek JS. Screening, diagnosis, and monitoring of gynecologic malignancies. Curr Opin Oncol 1989;1:75-81. 83. Lichtenstein A, Seelig M, Berek JS, Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood 1989;74:805-809. 84. Montz FJ, Berek JS. Vaginal reconstruction. Med Aspects Human Reprod 7:11-18, 1989. 85. Berek JS. Second-look laparotomy. Adv Oncology 1990;6:25-29. 86. Nio Y, Zighelboim J, Berek JS, Bonavida B. Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol 1990;26:1-8. 87. Heaps J, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol 1990;75:1023-1028. 88. Berek JS. Adjuvant therapy for early-stage ovarian cancer. N Engl J Med 1990;322:1076-78, editorial. 89. Eisner RF, Montz FJ, Berek JS. Cytoreductive surgery for advanced ovarian cancer: Cardiovascular evaluation with pulmonary artery catheters. Gynecol Oncol 1990;37:311-314. 90. Munoz AK, Berek JS, Fu YS, Heintz APM. Pelvic hemangiopericytomas: A report of five cases and literature review. Gynecol Oncol 1990;36:380-382. 91. Binder SW, Huang I, Fu YS, Hacker NF, Berek JS. Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol 1990;37:9-16. 92. Fu YS, Gambone JC, Berek JS. Pathophysiology and management of endometrial hyperplasia and carcinoma. West J Med 1990;153:50-61. 93. McGuire III WP, Blessing JA, Berek JS, Munoz A. Phase II study of N-Methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. Invest New Drugs 1990;8:191-194. 23
  • 24. Jonathan S. Berek, MD, MMS 94. Nio Y, Zighelboim J, Berek JS, Bonavida B. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Anticancer Res 1990;10:441-446. 95. Brown JV, Fu YS, Berek JS. Ovarian metastasis are rare in stage I adenocarcinoma of the cervix. Obstet Gynecol 1990;76:623-626. 96. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constituitive production of Interleukin-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Research 1990;50:6959-6965. 97. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol 1990;38:333-339. 98. Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990;38:309-314. 99. Parker WJ, Berek JS. Management of selected cystic adnexal masses in postmenopausal women by operative laparoscopy: a pilot study. Am J Obstet Gynecol 1990;163:1574-1577. 100. Berek JS. Intraperitoneal adoptive immunotherapy for peritoneal cancer. J Clin Oncol 1990;8:1610-1612. 101. Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER-2/neu oncogenes. Cancer Research 1990;50:7364-7370. 102. Nio Y, Zigelboim J, Berek JS, Bonavida B. Sensitivity of ovarian tumor cells to effector cells generated by various response modifiers. Nat Immun Cell Growth Reg 1990;9:283-296. 103. Berek JS, Heaps JM. Surgical staging of cervical cancer. Clin Obstet Gynecol 1990;33:852-863. 104. Shih S, Vetto JT, Berek JS, Heaps JM, Hiatt JR. Adnexal torsion: An unusual cause of abdominal pain in postmenopausal women. J Am Coll Surg 1991;57:327-329. 105.Berek JS, Welander C, Schink JC, Grossberg H, Montz FJ, Zighelboim J. A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 1991;40:237-243. 106. Takami C, Nieberg RK, Berek JS. Correlation of endocervical curettage with subsequent cone biopsy in the investigation of abnormal cervical cytology. Int J Gynecol Oncol 1991;1:97-103. 107. Layfield LJ, Heaps JM, Berek JS. Fine-needle aspiration cytology accuracy with palpable gynecologic neoplasms. Gynecol Oncol 1991;40:70-73. 108. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:1038-1043. 109. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jashan A, Mortel R. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival: A Gynecologic Oncology Group study. Am J Obstet Gynecol 24
  • 25. Jonathan S. Berek, MD, MMS 1991;164:997-1004. 110. Berek JS, Heaps JM, Fu YS, Juillard GJF, Hacker NF. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 1991;42:197-201. 111. Tsuchitani T, Zighelboim J, Berek JS, Bonavida B. Potentiation of cytotoxicity against human ovarian cell-lines with combinations of subtoxic concentrations of tumor necrosis factor and adriamycin or cisplatinum. J Cell Pharmacol 1991;2:268-278. 112. Martinez-Maza O, Berek JS. Interleukin 6 and cancer treatment. In Vivo 1991;5:583-588. 113. Marcus AC, Crane LA, Kaplan CP, Reading AE, Savage E, Gunning J, Bernstein G, Berek JS. Improving adherence to screening follow-up among women with abnormal pap smears: results from a large clinic-based trial of three intervention strategies. Med Care 1992;30:216-230. 114. McGonigle KF, Berek JS. Early-stage squamous cell and adenocarcinoma of the cervix. Curr Opin Obstet Gynecol 1992;4:109-119. 115. Berek JS. Second-look versus second-nature. Gynecol Oncol 1992;44:1-2,editorial. 116.Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant α-interferon. Gynecol Oncol 1992;45:3-8. 117. Berek JS. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur J Cancer 1992;28:719-721. 118.Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6 and tumor necrosis factor-α. Am J Obstet Gynecol 1992;166:997-1007. 119. Berek JS, Watson JM, Martinez-Maza O. The role of interleukin 6 (IL-6) in the growth and development of ovarian cancer. Ovarian Ca 1992;2:101-113. 120. Berek JS, Markman M. Intraperitoneal interferon and cisplatin in residual epithelial ovarian cancer at second-look laparotomy. Ovarian Ca 1992;2:324-45. 121. Bookman M, Berek JS. Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin N Am 1992;6:941-965. 122. Gotlieb WH, Abrams JS, Watson JM, Velu T, Martinez-Maza O, Berek JS. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992;4:385-390. 123.Safrit JT, Berek JS, Bonavida B. Sensitivity of drug resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-α) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecol Oncol 1992;48:214-220. 124. Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, 25
  • 26. Jonathan S. Berek, MD, MMS Bast RC. Constituitive production of macrophage colony stimulating factor (M-CSF) and interleukin-6 (IL-6) by human ovarian surface epithelial cells. Experimental Cell Research 1993;207:332-339. 125. Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 1993;49:8-15. 126. Monk BJ, Nieberg RK, Berek JS. Primary leiomyosarcoma of the ovary in a perimenarchal female. Gynecol Oncol 1993;48:389-393. 127. Berek JS. Intraperitoneal immunotherapy with cytokines. J Infus Ther 1993;3:63-68. 128. Herbst AL, Berek JS. Impact of contraception on gynecologic cancers. Am J Obstet Gynecol 1993;168:1980-1985. 129. Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (A Gynecologic Oncology Group Study). Gynecol Oncol 1993;49:279-283. 130. Eisner RF, Braly P, Berek JS. Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Gynecol Oncol 1993;48:338-341. 131. Berek JS, Markman M. Intraperitoneal administration of biological agents. Int J Gynecol Cancer 1993;2 Suppl 1:26-29. 132. Markman M, Berek JS. Intraperitoneal administration of the biologic agents, tumor necrosis factor, gamma interferon and interleukin-2. Int J Gynecol Cancer 1993;2 Suppl 1:30-34. 133. Allen DG, Baak J, Delpomme D, Berek JS, et al. Advanced epithelial ovarian cancer: 1993 consensus. Annals Oncol 1993;4(4):S83-S88. 134. Berek JS, Martinez-Maza O, Hamilton T, Trope C, Kaern J, Baak J, Rustin GJS. Molecular and biological factors in the pathogenesis of ovarian cancer. Annals Oncol 1993;4:S3-S16. 135. Luff RD, Berek JS, Bibbo M, et al. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. Acta Cytologica 1993;37:115-124. 136. Rustin GJS, van der Burg MEL, Berek JS. Tumour markers. Annals Oncol 1993;4:S71-77. 137. Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma (serous) of mullerian type: a subgroup of women presenting with peritoneal carcinomatosis. Int J Cancer 1994;4:43-51. 138. Berek JS, Martinez-Maza O. Molecular and biological factors in the pathogenesis of ovarian cancer. J Reprod Med 1994;39:241-248. 139.Gotlieb WH, Watson JM, Rezai BA, Johnson MT, Martinez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: Up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-α. Am J Obstet Gynecol 1994;170:1121-1128. 140. Farias-Eisner R, Cirisano F, Grouse D, Leuchter RS, Karlan BY, Lagasse LD, Berek JS. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2 N0-1 M0) disease. Gynecol Oncol 1994;53:55-58. 26
  • 27. Jonathan S. Berek, MD, MMS 141. Parker WH, Berek JS. Laparoscopic management of the adnexal mass. Obstet Gynecol Clin N Am 1994;21:79-92. 142. Hoskins WJ, McGuire W, Brady M, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1994;170:974-980. 143. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414-418. 144. Farias-Eisner R, Young BK, Berek JS. Surgical management of ovarian cancer. Seminars Surg Onc 1994;10:1-8. 145. Casey AC, Berek JS. Papillary serous cystadenocarcinoma arising in benign glandular inclusion in pelvic and inguinal lymph nodes. Obstet Gynecol 1994;84:724-726. 146. Broun ER, Belinson JL, Berek JS, McIntosh D, Hurd D, Ball H, Williams S. Salvage therapy for recurrent and refractory ovarian cancer with high dose chemotherapy and autologous bone marrow support: A Gynecologic Oncology Group Pilot Study. Gynecol Oncol 1994;54:142-146. 147. Farias-Eisner R, Teng F, Olivera M, Leuchter R, Karlan B, Lagasse LD, Berek JS. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-110. 148. Gotlieb WH, Berek JS. Advances in the biology of gynecologic cancer. Curr Opin Oncol 1994; 6:513-518. 149.Hourizadeh A, Broquet C, Mencia-Huerta JM, Braquet P, Berek JS, Bonavida B. Cytotoxicity of new aza-alkyl lysophospholipds against drug sensitive and resistant human ovarian tumor cell lines: role of free radicals and potentiation of cytotoxicity by TNF-α and CDDP. Oncol Rep 1994;1:1253- 1259. 150. Berek JS. Interval debulking of ovarian cancer - an interim measure. N Engl J Med 1995;332:675-77, editorial. 151. Berek JS. The art and science of medical techniques. J Gynecol Tech 1995;1:1, editorial. 152. Parker WH, Levine RL, Howard FM, Sansone B, Berek JS. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994; 179:733-737. 153. Safrit JT, Tsuchitani T, Berek JS, Zighelboim J, Bonavida B. Overcoming drug resistance by the synergistic activity of drug and tumor necrosis factor. J Immunol 1995; 34:456-60. 154. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. Assessment of dose intensive therapy in suboptimally debulked ovarian cancer: A gynecologic oncology group study. J Clin Oncol 1995;13(7):1589-99. 155. Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial. Gynecol Oncol 1995;34:143-7. 27
  • 28. Jonathan S. Berek, MD, MMS 156. Berek JS. Ovarian cancer spread: is laparoscopy to blame? Lancet 1995; 346, 200, editorial. 157. Kim YB, Berek JS. Chemotherapy for epithelial ovarian cancer: An update. Contemp Oncol 1995;10:28-34. 158. Berek JS, Bast RC Jr. Ovarian cancer screening: The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995; 76:2092-6. 159.Bonavida B, Safrit J, Morimoto H, Mizutani Y, Yonehara S, Berek JS. Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-α/anti-Fas antibody and chemotherapeutic drugs or toxins. Ovarian Ca 1995; 3:295-303. 160. Berek JS. Radiation therapy for adenocarcinoma of the uterine cervix: does the histology matter? Int J Rad Oncol Biol Phys 1995;32:1543-4. 161. Sharp F, Blackett AD, Leake RE, Berek JS. Conclusions and recommendations from the Helene Harris Memorial Trust fifth biennial international forum on ovarian cancer. Int J Gynecol Cancer 1995;5:449-58. 162. Watson JM, Gotlieb WH, Abrams JH, Johnson MT, Kaldi K, Berek JS, Martinez-Maza O. Immune analysis of ascitic fluid from patients with ovarian cancer: relationship between cytokines, acute phase proteins, immunoglobulins, immunosuppression, and tumor classification. Gynecol Oncol 1996; 34:145-51. 163. McGonigle KF, Lavey RS, Juillard GJF, Berek JS. Complications of pelvic radiation therapy for gynecologic malignancies in elderly women. Intl J Gynecol Cancer 1996; 6:149-155. 164. Fowler JM, Nathan L, Nieberg RK, Berek JS. Mixed mesodermal sarcoma of the ovary in a young patient. Europ J Obstet Gynecol Reprod Biol 1996; 65:249-253. 165. Gallion HH, Guarrino DA, DePriest PD, van Nagell JR, Vaccarello L, Berek JS, Pieretti M. Evidence for a unifocal origin in familial and inherited ovarian cancers. Am J Obstet Gynecol 1996; 58:34-9. 166. Kim YB, Berek JS, Martinez-Maza O, Satyaswaroop PG. Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Gynecol Oncol 1996;60:324-9. 167. Berek JS. Complete debulking of advanced ovarian cancer. Cancer J 1996; 2:134-5. 168. Casey AC, Bhodauria S, Shapter A, Nieberg R, Berek JS, Farias-Eisner R. Dysgerminoma: the role of conservative surgery. Gynecol Oncol 1996; 63: 352-7. 169. Berek JS. Adjuvant radiation therapy in gynecologic malignancy. Hung J Gynecol Oncol 2:97- 106, 1996. 170. Dorigo O, Berek JS. Gene therapy for ovarian cancer: development of novel treatment strategies. Int J Gynecol Cancer 1997; 7:1-13. 171. Marcus AC, Kaplan CP, Crane LA, Berek JS, Bernstein G, Gunning J, McClatchey. Reducing loss-to-follow-up among women with abnormal pap smears: results from a randomized trial testing an intensive follow-up protocol and economic incentives. Medical Care 1997; 18:156-40. 28
  • 29. Jonathan S. Berek, MD, MMS 172. Bonavida B, Safrit J, Morimoto H, Mizutani Y, Usla R, Borsello N, Frost P, Berek JS, Belldegrun A, Zighelboim J, Ng CP, Mori S. Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to reverse resistance and implications in gene therapy. Oncol Reports 1997:4:201-5. 173. Sharp F, Blackett AD, Berek JS, Bast RC Jr. Conclusions and recommendations from the Helene Harris memorial trust sixth biennial international forum on ovarian cancer. Int J Gynecol Cancer 1997;7:416-424. 174. Dorigo O, Berek JS. Vaccine therapy for gynecologic cancer. Oncology 1997;13:41-43. 175. Chen L-M, Berek JS. Progress in ovarian cancer. Current Opin Obstet Gynecol 1998;10:51-55. 176. Horton H, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker S. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile J Immunol 1999;163:6378-6385. 177. Bristow RE, Berek JS. The role of surgery in the management of immature teratomas of the ovary. CME J Gynecol Oncol 1998; 3:21-28. 178. Berek JS. Techniques of adjuvant radiation therapy in gynecologic malignancy. J Gynecol Tech 1998;4(2):1-11 179. Berek JS. Pap testing: How can we make it better? J Gynecol Tech 1998;4(2):1-2 180. Poggi SH, Bristow RE, Neiberg RK, Berek JS. Psammocarcinoma with an aggressive course. Obstet Gynecol 1998; 92(4):659-663. 181.Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor β antisense and Interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 1998;71(2):204-210. 182. Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1998; 71:410-415. 183. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Annals Oncol 1998;10:3-8. 184. Dorigo O, Berek JS. Ovarian Cancer gene therapy: molecular scissors of the new millennium? J Gynecol Tech 1998;4:149-162. 185. Dorigo O, Berek JS. Molecular strategies for treatment of ovarian cancer: potential of immuno-gene therapy and correction of genetic defects. CME J Gynecol Oncol 1999;4:125-134. 186. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer E, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Annals Oncol 1999;10:87-92. 187. Hamilton TC, Berek JS, Kaye SB. Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Annals Oncol 1999;10:69-74. 188. Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P. 29
  • 30. Jonathan S. Berek, MD, MMS Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma. A Phase II gynecologic oncology group study. Gynecol Oncol 1999;74:48-52. 189. Berek JS, Markman M, Stonebraker B, Lentz S, Adelson MD, DeGeest K, Moore D. Intraperitoneal alpha-interferon in residual ovarian carcinoma: A phase II Gynecologic Oncology Group Study. Gynecol Oncol 1999;75:10-14. 190. Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine pathway. J Immunol 1999;163:6378-6385. 191. Berek JS. Preoperative prediction of optimal resectability in advanced ovarian cancer using CA125. editorial. Gynecol Oncol 2000;77:225-226. 192. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Sem Surg Oncol 2000;19:3-10. 193. Berek JS. The health care crisis- what can be done to address the problem? editorial. J Gynecol Tech 2000;6:1-2. 194. Bristow RE, Berek JS. The role of surgery in the management of immature teratoma of the ovary. J Gynecol Tech 2000;6:37-42. 195. Peters WA III, Liu PY, Barrett RJ, Gordon W Jr, Stock R, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy alone as adjuvant therapy following radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613. 196. Berek JS. Intestinal obstruction in the patient with ovarian cancer. Oncol 2000;14:54-8. 197.Garban HJ, Fukuto J, Berek JS, Bonavida B. Interferon-gamma-induced nitric oxide sensitizes the AD10 ovarian carcinoma cell line to TNF-α-mediated cytotoxicity. J Immunol 2000;74:121-6. 198. Ghosh K, Dorigo O, Bristow R, Berek JS. A radical debulking of leiomyomatosis disseminata due to a colonic obstruction: a case report and review of the literature. J Am Coll Surg 2000;28:17-21. 199. Chen LM, Nelson SD, Berek JS. Recurrent mature cystic ovarian teratoma presenting with a perihepatic mass. Obstet Gynecol 2000;95:1021-4. 200. Poggi SH, Bristow RE, Nieberg RK, Bashey A, Berek JS. Acute myelogenous leukemia following treatment of small-cell neuroendocrine carcinoma of the cervix. Gynecol Oncol 2000;78:156-9. 201. Berek JS, Bristow RE. The role of surgery in the management of immature treatment of the ovary. CME J Gynecol Oncol 2000;181-6. 202. Berek JS. Interferon plus chemotherapy for primary treatment of ovarian cancer. Lancet 2000;356:9223:6-7. 203. Memarzadeh S, Berek JS. Epithelial ovarian cancer. J Reprod Med 2001;61:7-15. 204. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias- Eisner R. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 2002;12:454-458. 30
  • 31. Jonathan S. Berek, MD, MMS 205. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003;13:120-124. 206. Tarjan D, Berek JS. Surgical resection of solitary brain metastasis from cervical cancer. Int J Gynecol Cancer. 2003;13:368-370. 207. Berek JS. Simplification of the new Bethesda 2001 classification system. Am J Obstet Gynecol 2003;188:S2-5. 208. Berek JS, Dorigo O, Schultes B, Nicodemus C. Immunological therapy for ovarian cancer. Gynecol Oncol 2003: 88:S105-109. 209. Balkwill F, Schlom J, Berek JS, Epenetos A, Bookman M, Freedman R, Wilbanks G. Immunological therapeutics in ovarian cancer. Gynecol Oncol 2003;88:S110-113. 210. Berek JS, Parham GP, Felix JC. Shedding a new light on Bethesda III: new technologies in cervical cancer screening. Am J Obstet Gynecol 2003;188:S6-7 211. Berek JS. Oregovomab. Am J Cancer 2003;2(2):135-136. 212. Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapy for ovarian cancer. J Clin Oncol 2003; 21:168-174s. 213.Memarzadeh S, Nastarajan S, Dandade DP, Ostrzega N, Saber PA, Busitttil A, Lentz SE, Berek JS. Lymph-vascular and perineural invasion in the parametria: a surgical and pathologic prognostic factor for early stage cervical cancer. Obstet Gynecol 2003; 102:612-619. 214. Gold MA, Walker JL, Berek JS, Hallum AV, Garcia DJ, Alberts DS. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol 2003; 90:325-330. 215. Balkwill F, Bast R, Berek JS, Chevenix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer: a position paper from the Helene Harris Memorial Trust. Int J Cancer 2003, 39:1818-1827. 216. Berek JS. Cervical cancer. Cancer J 2003: 326-327. 217. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePreist PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey SJ, King L. Progress in the mangement of gynecologic cancer: consensus summary statement. J Clin Oncol 2003;21:129-32. 218. Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. A phase II evaluation of oxaliplatin in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2003;90:177-180. 219. Berek JS, Taylor PT, Gordon A, Cunningham M, Finkler N, Orr J, Rivkin S, Schultes BC, Whiteside TL, Nicodemus C. Randomized placebo-controlled study of Oregovomab for consolidation of clinical remission in patients with ovarian cancer: prolonged disease-free survival in optimal chemosensitive patients. J Clin Oncol 2004;22:3507-3516. 220. Robinson A, Metten S, Guiton G, Berek JS. Using fresh tissue dissection to teach human anatomy 31
  • 32. Jonathan S. Berek, MD, MMS in the clinical years. Academic Med 2004;79:711-716. 221. Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Muderspach LI, Penson RT, Robinson WR, Rodriquez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res 2004;10:2681-2686. 222. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML. Evaluation of vinorelbine in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:108-111. 223. Nicodemus C, Berek JS. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 2005:5:1-10. 224. Parker W, Broder M, Liu Z, Shoupe D, Farquar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-226. 225. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005, 99:153-159. 226. Elkas JC, Berek JS, Leuchter R, Lagasse LD, Karlan BY. Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. Gynecol Oncol 2005;97:685-692. 227. Lenzi R, Baile WF, Berek JS, Back A, Buckman R, Cohen L. Design, conduct and evaluation of a communication course for oncology fellows. J Cancer Educa 2005;20:143-149. 228. Monk BJ, Im S, Wang J, Stock R, Peters W, Barrett RJ, Berek JS, Souhami L, Grigsby P, Gordon W, Alberts DS. Rethinking the use of chemotherapy and radiation after radical hysterectomy: A clinical-pathological analysis of SWOG 8797/GOG 109. Gynecol Oncol 2005;96:721-728. 229. Orr J, Chaimberlain D, Kilgore L, Naumann W, Walker J, Berek JS. Management of endometrial cancer. Clinical guidelines for the obstetrician gynecologist. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin 2005;65:1-13. 230. Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer 2006;16:1. Journal, peer reviewed, in press 231. Fleming GF, Sill MW, Thigpen JT, Adler LM, Berek JS, DiSilestro PA, Horowitz I. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006, in press. 232. Sherman ME, Abdul-Karim F, Berek JS, Powers C, Sidaway MK, Tabbara S. Atypical squamous cells: the Bethesda System 2001 nomenclature. Acta Cytolog 2006, in press. 233. Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble T, Berek JS. Progress in ovarian cancer research: proceedings of the 5th Bienneal Ovarian Cancer Research Symposium. Int J Gyn Cancer 2006, in press. 234. Balkwill F, Bast R, Berek JS, Gore M, Hamilton T, Jacobs I, Mills G, Urban NJ. Current research 32
  • 33. Jonathan S. Berek, MD, MMS and treatment for epithelial ovarian cancer: a position paper from the Helene Harris Memorial Trust, 2006. Int J Cancer, in press. 235. Bryan DN, Lentz SE, Natarajan S, Ostrzega N, Berek JS, Memarzadeh S. A clinicopathologic analysis of Non-Hodgkin’s lymphomas involving the female reproductive tract. Int J Gyn Cancer, 2006, in press. On line publications, Peer reviewed, revised annually 236. Berek JS. Staging and treatment of gestational trophoblastic disease. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 237. Berek JS. Epidemiology and pathology of gestational trophoblastic disease. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 238. Chen LM, Berek JS. Treatment of endometrial cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 239. Chen LM, Berek JS. Treatment of locally recurrent or advance endometrial cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 240. Chen LM, Berek JS. Staging, treatment, and follow-up of endometrial cancer-III. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 241. Chen LM, Berek JS. Diagnosis and staging of ovarian cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 242. Chen LM, Berek JS. Ovarian tumors of low malignant potential. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 243. Dorigo O, Berek JS. Sex cord-stromal tumors of the ovary-I. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 244. Dorigo O, Berek JS. Sex cord-stromal tumors of the ovary-II Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 245. Elkas J, Berek JS. Clinical manifestations, diagnosis, pathology, and staging of vulvar cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 246. Elkas J, Berek JS. Vulvar cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 247. Elkas J, Berek JS. Vaginal cancer. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 248. Holschneider CH, Hunter MI, Berek JS. Vaginal intraepithelial neoplasia. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 33
  • 34. Jonathan S. Berek, MD, MMS 249. Holschneider CH, Hunter MI, Berek JS. Vulvar intraepithelial neoplasia. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 250. Memarzadeh S, Mundt AR, Berek KS. Classification, clinical manifestations, and staging of uterine sarcoma. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 251. Memarzadeh S, Mundt AR, Berek KS. Treatment of uterine sarcoma-I. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 252. Memarzadeh S, Mundt AR, Berek KS. Treatment of uterine sarcoma-II. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. 253. Memarzadeh S, Berek KS. Cancer of the fallopian tube. Gynecologic Oncology. UpToDate Clinical Reference Library. UpToDate Publishers, Wellesley, MA, 2005, updated annually. Journal publications, non-peer-reviewed 254. Garcia-Bunuel R, Berek JS, Woodruff JD. Luteomas of pregnancy, Yearbook Obstet Gynecol 1976;4:44-45. 255. Hacker NF, Berek JS, Lagasse LD. How deep to dissect inguinal and femoral nodes in vulvar cancer. Contemp Obstet Gynecol 1981;18:19. 256. Berek JS, Hacker NF, Ford LC, Lagasse LD. Recent progress in the treatment of epithelial ovarian malignancies. Cancer Bulletin 1981;8:6-8. 257. Hacker NF, Berek JS, Lagasse LD. Surgical staging for cervical cancer. Contemp Obstet Gynecol 1982:95. 258. Berek JS, Hacker NF, Lagasse LD. Ovarian Cancer: improving survival with cytoreductive surgery. Contemp Obstet Gynecol 1983:229-238. 259. Berek JS, Lagasse LD, Hacker NF, Leuchter RS. Levator ani transposition for anal incompetence secondary to sphincter damage. Yearbook Obstet Gynecol 983:235-237. 260. Hacker NF, Leuchter RS, Berek JS, Castaldo TW, Lagasse LD. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Yearbook Obstet Gynecol 1983:237-238. 261. Berek JS. Helping a patient surrender her child for adoption. Contemp Obstet Gynecol 1983;12:412. 262. Hacker NF, Berek JS, Lagasse LD. Ovarian cancer--more on cytoreduction. Contemp Obstet Gynecol 1983;27:68-82. 263. Berek JS, Hacker NF, Lagasse LD. Surgical staging of early ovarian cancer. Contemp Obstet Gynecol 1984;32:87. 34
  • 35. Jonathan S. Berek, MD, MMS 264. Berek JS. Adenocarcinoma of the cervix. Contemp Obstet Gynecol, 1985:13:37-44. 265. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second-look laparotomy in stage III epithelial ovarian cancer. Proc Internat Gynecol Cancer. 1985:183-88. 266. Berek JS. Surgical staging of cervical cancer. Gynecol Oncol, Proc J Boorhaave1985;3:201-209. 267. Berek JS. Salvage therapy in ovarian cancer. Gynecol Oncol, Proc J Boorhaave 1985;3:209-218. 268. Berek JS, Woodruff JD, Lagasse LD, Richart RM. Detecting adenocarcinoma of the cervix early. Contemp Obstet Gynecol, 1985:8:113-133. 269. Curry SL, Berek JS, Hoskins WJ. Second-look in ovarian cancer, in Symposium on Ovarian Cancer ACOG Update, Am Coll Obstet Gynecol, 1986;11(7):1-9. 270. Berek JS. Intraperitoneal interferon. Interferon Letter 1986;3(1):5. 271. Clarke-Pearson DL, Berek JS. Second-Look laparotomy and debulking for ovarian cancer. Obstet Gynecol Illust 1989;9:1-32. 272. Patsner B, Berek JS, Niloff JM. CA-125: Clinical applications. Update, Am Coll Obstet Gynecol 1989;14:1-9. 273. Berek JS, Bast RC, Bagshawe KD. Monoclonal antibodies in gynecology: applications and future directions. Contemp Obstet Gynecol 1990;15:43-51. 274. Berek JS. Second-look operations in ovarian cancer. Advances in Oncology 1990;6:25. 275. Berek JS. Ovarian carcinoma: the search for prevention, detection, and durable remission. Oncol Times 1992;14(2):2-30. 276. Berek JS. Squamous carcinoma of the ovary. Oncol Times 1994;16(12):35-6. 277. Anastasia PJ, Berek JS. An update: women's reproductive cancers. Coping 1995; 9(3):53-5. 278. Bristow RE, Berek JS. Surgical management of dysgerminoma. Contemp Obstet Gynecol 1998;43(2):98-119. 279. Berek JS, Schwartz P, Horowitz I. Screening and early detection of gynecologic malignancies. ACOG Update:1998;23(1):1-9. 280. Chen LM, McGonigle KF, Berek JS. Endometrial cancer: developments in evaluation and treatment. Oncology 1999, 28-34. 281. Berek JS. Vaccine therapy. Cure: survivors 2002:38-44. 282. Bryan D, Berek JS. Review: Management of intestinal obstruction in ovarian cancer. Oncology 2003. 283. Berek JS, Hacker NF, Zighelboim J, Ford LC, Lagasse LD. Intraperitoneal therapy protocols for treatment of patients with residual ovarian cancer: An update. UCLA Cancer Center Bulletin 1983;10:7. 35
  • 36. Jonathan S. Berek, MD, MMS 284. Hacker NF, Berek JS, Lagasse LD. The management of vulvar cancer: Current perspectives, UCLA Cancer Center Bulletin 1983:10:3. 285. Hacker NF, Berek JS, Lagasse LD. Psychosexual considerations in gynecologic oncology, UCLA Cancer Center Bulletin 1984:10. 286. Berek JS. The modern role of surgery in ovarian cancer. UCLA Health Insights 1984;2:5. 287. Berek JS. Elevated CA-125 in an asymptomatic woman. Cancer Consultations 1994;1:99. 288. Berek JS. Gynecologic Malignancies. Audio-Digest Obstet Gynecol 1994;41:13. 289. Berek JS. Screening for ovarian cancer: some words of caution. Oncol Times 1994;16:2-15. 290. Berek JS. Gynecologic cancers. Ted Mann Family Resource Center News. 2002;23:6-7. 291. Berek JS, ed. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. American College of Obstetrics and Gynecology. 2002. 292. Berek JS. New technique detects ovarian cancer. United Press International. November 19, 2002. 293. Berek JS. Uterine papillary serous carcinoma. Treatment reporter: oncology 2003;4:1-4. Monographs 294. Berek JS, Gritz ER, Bast RC, Kurman R, Rimer BK. Cancer Screening for Women: Guidelines and Effect on Mortality. Syntex Annual Women's Healthcare Roundtable Monograph. Syntex 1991;1:57-127. 295. Alberts DS, Berek JS, Dorr RT, Hamilton TC, Herzog TJ, Howell SB, McGuire WP, Schink JC. New horizons in the treatment of refractory ovarian cancer: exploring the platinum-free interval. Arizona Cancer Center Monograph. University of Arizona Health Sciences Center. Arizona Board of Regents. 2000:1-31. 296. Berek JS, Gordon AN, McGuire WP, Ozols RF, Thigpen JT. Gynecologic malignancies: commentary and review of chemotherapy presentations at the Society of Gynecologic Oncologists, 2000. UCLA Symposium Monograph. UCLA School of Medicine. Office of Continuing Medical Education. 2000. 297. Berek JS. The patient active guide to living with ovarian cancer. The Wellness Community. 2002. 298. Berek JS. Ovarian cancer clinical review. Duke University School of Medicine, Office of Continuing Medical Education. Interactive Network for Continuing Education. Monmouth, NJ, 2002. 299. Berek JS. Pain management. Part I. Overview of physiology, assessment and treatment. American Medical Association. 2003;3. Literary magazine, Poem 300. Berek JS. No words (poem). UCLA Beat. 2002;4:29. 36
  • 37. Jonathan S. Berek, MD, MMS Books 301. Berek JS. Gynecologic Malignancies. Section Editor. In: Haskell CM, ed. Cancer Treatment, Second Edition, W.B. Saunders, Philadelphia, 1985. 302. Berek JS. Gynecologic Oncology. Section Editor. In: Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, First Edition. Philadelphia: W.B. Saunders, 1986. 303. Berek JS, Hacker NF. Practical Gynecologic Oncology, Williams and Wilkins, publishers, Baltimore, MD, l989; Second Printing, 1990. 304. Berek JS. Gynecologic Malignancies. Section Editor. In: Haskell CM, ed. Cancer Treatment, Third Edition, W.B. Saunders, Philadelphia, 1990. 305. Greer B, Berek JS. Gynecologic Oncology: Treatment Rationale and Technique. Amsterdam: Elsevier, 1991. 306. Berek JS. Gynecologic Oncology. Section Editor. In: Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, Second Edition. Philadelphia: W.B. Saunders, 1991. 307. Berek JS, Hacker NF. Practical Gynecologic Oncology, Second Edition, Williams and Wilkins, publishers, Baltimore, MD, 1994. 308. Sharp F, Mason P, Blackett A, Berek JS. Ovarian Cancer 3: Biology, Diagnosis and Management. London: Chapman & Hall Medical, 1994. 309. Berek JS. Gynecologic Malignancies. Section Editor. In: Haskell CM, ed. Cancer Treatment, Fourth Edition, W.B. Saunders, Philadelphia, 1995. 310. Sharp F, Blackett A, Leake R, Berek JS. Ovarian Cancer 4. London: Chapman & Hall Medical, 1996. 311. Berek JS (ed): Novak's Gynecology, 12th edition, Williams & Wilkins, Baltimore, 1996. 312. Parker WH, Berek JS. Management of the pelvic mass by operative laparoscopy. In: Soderstrom RM, ed. Operative Laparoscopy. 2nd ed. New York: Raven, 1996. 313. Berek JS. The management of epithelial ovarian cancer. In: B. Ottesen, A. Tabor (eds.) New Insights in Gynecology and Obstetrics, Research and Practice, United Kingdom:Parthenon Publishing, 1997 314. Sharp F, Blackett A, Berek JS, Bast RC. Ovarian Cancer 5. London: Chapman & Hall Medical, 1998. 315. Olive D, Berek JS. Study Guide to Novak’s Gynecology, Berek JS, editor, Williams and Wilkins, Baltimore, 1998. 316. Gore ME, Schwartz P, Berek JS, Kavanagh J. Ovarian Tumours, ISIS Medical Media, London, 2000. 317. Berek JS. ed., Gynecologic cancers Section. In Handbook of Cancer Therapy. Cashaito D., ed., Little, Brown, Co. Boston, 2000. 37
  • 38. Jonathan S. Berek, MD, MMS 318. Berek JS, Hacker NF. Practical Gynecologic Oncology, third edition, Lippincott Williams & Wilkins, Philadelphia, 2000. 319. Berek JS, Runowicz C, eds, Gynecologic Oncology and Pelvic Surgery, fourth ed, PROLOG, American College of Obstetricians and Gynecologists, Washington, DC, 2000. 320. Berek JS, et al, eds. Women’s Health Encyclopedia. American College of Obstetricians and Gynecologists, Washington, DC, 2000. 321. Berek JS. Gynecologic Malignancies. Section Editor. In: Haskell CM, ed. Cancer Treatment, Fifth Edition, W.B. Saunders, Philadelphia, 2000 322. Berek JS. Novak’s Gynecology, 13th, Lippincott Williams and Wilkins, Philadelphia 2002. 323. Berek JS. Novak’s Gynecology Study Guide. Second edition. Lippincott Williams and Wilkins, Philadelphia 2002. 324. Berek JS, ed. Precis: Gynecologic Oncology. Fifth edition. American College of Obstetricians and Gynecologists, Washington, DC, 2003. 325. Berek JS, Hacker NF. Practical Gynecologic Oncology, fourth edition, Lippincott Williams & Wilkins, Philadelphia, 2005. 326. Berek JS. Berek & Novak’s Gynecology. 14th edition. Lippincott Williams and Wilkins, Philadelphia 2006, in press. Book Chapters 327. Berek JS, editor, Section on Gynecologic Oncology. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 409-481. 328. Berek JS, Hacker NF, Lagasse LD. Ovarian cancer. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 409-429. 329. Berman ML, Ballon SC, Berek JS, Hacker NF, Lagasse LD. Carcinoma of the uterine cervix. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 429-442. 330. Berman ML, Ballon SC, Berek JS. Neoplasms of the uterine corpus. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 443-457. 331. Hacker NF, Berek JS, Lagasse LD. Vulvar cancer. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 470-475. 332. Ballon SC, Berman ML, Berek JS. Carcinoma of the vagina. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 470-475. 333. Ballon SC, Berman ML, Berek JS. Gestational trophoblastic neoplasia. In: Haskell CM, editor. Cancer Treatment, Second edition. Philadelphia: W.B. Saunders, 1984: 476-481. 334. Berek JS, Hacker NF. Immunotherapy of gynecologic cancer. In: Deppe G, editor. Chemotherapy of Gynecologic Cancer. New York: AR Liss, Inc., 1984: 363-374. 38
  • 39. Jonathan S. Berek, MD, MMS 335. Hacker NF, Berek JS. Cytoreductive surgery for ovarian cancer. In: Alberts D, Surwit EA, editors. Ovarian Cancer. New York: Macmillan and Company, 1985: 53-67. 336. Berek JS, Hacker NF. Staging and second-look operations in ovarian cancer. In: Alberts D, Surwit EA, editors. Ovarian Cancer. New York: Macmillan and Company, 1985: 69-90. 337. Hacker NF, Berek JS, Lagasse LD. Gastrointestinal operations in gynecologic oncology. In: Knapp RC, Berkowitz RS, editors. Gynecologic Oncology, New York: MacMillan and Co., 1986: 471-491. 338. Berek JS, Hacker NF, Lagasse LD. Reconstructive pelvic surgery. In: Knapp RC, Berkowitz RS, editors. Gynecologic Oncology, New York: MacMillan and Co. 1986: 579-596. 339. Heintz APM, Berek JS. Cytoreductive surgery for ovarian carcinoma. In: Piver S, ed. Ovarian Cancer, 1986: 129-143. 340. Berek JS. Ovarian Cancer. In: Hacker NF, Moore JG, editors. Essentials of Obstetrics and Gynecology. Saunders and Co., 1986: 488-497. 341. Berek JS. Gestational trophoblastic neoplasia. In: Hacker NF, Moore JG, editors. Essentials of Obstetrics and Gynecology. Saunders and Co., 1986: 509-516. 342. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second-look laparotomy in stage III epithelial ovarian cancer. In: Morrow CP and Smart GE, editors. Gynecologic Oncology New York: Springer-Verlag, 1986. 343. Berek JS, Hacker NF. Sarcomas of the female genital tract. In: Eilber FR, Morton DL, Sondak VK, Economou JS: editors. The Soft Tissue Sarcomas. 1987: 229-238. 344. Hacker NF, Berek JS. Surgical staging of cervical cancer. In: Alberts DS, Surwit EA, editors. Cervix Cancer. New York: MacMillan and Co., 1987: 43-57. 345. Berek JS, Hacker NF. Staging and second-look operations in ovarian cancer. In: Piver S, editor. Ovarian Cancer. 1987: 109-127 346. Berek JS. Intraperitoneal administration of interferon in ovarian cancer. In: Interferons in Cancer Treatment. Ontario: Med. Ed. Serv. (Canada) Inc., 1987: 117-130. 347. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology. Williams and Wilkins, 1989: 327-364. 348. Berek JS. Nonepithelial ovarian and tubal cancers. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology, Williams and Wilkins, 1989: 365-390. 349. Berek JS. General surgical operations. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology, Williams and Wilkins, Publishers, 1989: 509-548. 350. Berek JS, Hacker NF. Immunotherapy in gynecologic malignancies. In: Deppe G, editor. Chemotherapy in Gynecologic Cancer, Second edition, New York: Alan Liss, Inc, 1990. 351. Berek JS, Hacker NF. Immunotherapy in gynecologic malignancies. In: Deppe G, editor. Chemotherapy in Gynecologic Cancer, Third edition, New York: Alan Liss, Inc, 1990. 39
  • 40. Jonathan S. Berek, MD, MMS 352. Berek JS, Hacker NF. Ovary and Fallopian Tubes. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co, 1990: 295-325 (portions reproduced from references 138 and 139). 353. Berman ML, Walker JL, Berek JS. Cervix. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co., 1990: 325-337. 354. Berman ML, Berek JS. Uterine corpus. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co., 1990: 338-351. 355. Hacker NF, Berek JS. Vulva. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co., 1990: 351-361. 356. Hacker NF, Berek JS. Vagina. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co., 1990: 361-366. 357. Berek JS, Zighelboim J, Nio Y, Bonavida B. Immunologic control of ovarian cancer. In: Sharp F, Mason WP, Leake RE, editors. Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman and Hall Medical, 1990: 85-93. 358. Berek JS, Martinez-Maza O, Montz FJ. Biologic response modifiers and monoclonal antibodies. In: Coppleson M, editor. Gynecologic Oncology. London, England: Churchill Livingstone Press, 1991. 359. Greer B, Berek JS. Evolution of the primary treatment of invasive squamous cell carcinoma of the vulvar. In: Greer B, Berek JS, editors. Gynecologic Oncology: Treatment Rationale and Technique. Amsterdam: Elsevier, 1991. 360. Huang S, Fu YS, Berek JS. Applications of special new technologies and problems in gynecologic pathology. In: Greer B, Berek JS, editors. Gynecologic Oncology: Treatment Rationale and Technique. Amsterdam: Elsevier, 1991. 361. Berek JS, Hacker NF, Lagasse LD. Reconstructive pelvic surgery. In: Berkowitz RS, Knapp RC, editors. Gynecologic Oncology, Second Edition. New York: Pergamon-MacMillan Publishing Company, 1992. 362. Hacker NF, Berek JS, Lagasse LD. Gastrointestinal operations in gynecologic oncology. In: Berkowitz RS, Knapp RC, editors. Gynecologic Oncology, Second Edition. New York: Pergamon- MacMillan Publishing Company, 1992. 363. Berek JS, Martinez-Maza O, Montz FJ. The immune system and gynecologic cancer. In: Coppleson M, editor. Gynecologic Oncology, Second Edition. London: Churchill Livingstone, 1992. 364. Martinez-Maza O, Berek JS. Immunology. In: Copeland L, editor. Gynecology. Philadelphia: W.B. Saunders, 1992. 365. Berek JS, Andersen B. Sexual rehabilitation in gynecologic oncology. In: Hoskins W, Perez C, Young RC, editors. Gynecologic Oncology: Principles and Practice. Philadelphia: Lippincott, 1992. 366. Berek JS, Dembo A, Markman M, Ozols RF. Ovarian cancer. In: Holland JF, Frei E, Bast RC, et al, editors. Oncology: Principles and Practice. Philadelphia: Lippincott, 1992. 40
  • 41. Jonathan S. Berek, MD, MMS 367. Berek JS. Ovarian Cancer. In: Hacker NF, Moore JG, editors. Essentials of Obstetrics and Gynecology, Second Edition. Saunders and Company, 1992. 368. Berek JS. Trophoblastic Neoplasia. In: Hacker NF, Moore JG, editors. Essentials of Obstetrics and Gynecology, Second Edition. Saunders and Company, 1992. 369. Berek JS, Markman M. Intraperitoneal cisplatin and interferon-α in persistent epithelial ovarian cancer: summary of phase I-II trials. In: Sharp F, Mason WP, Creasman W, editors. Ovarian Cancer 2. London: Chapman & Hall, 1992. 370. Berek JS, Watson JM, Martinez-Maza O. Role of interleukin-6 in ovarian cancer. In: Sharp F, Mason WP, Creasman W, eds. Ovarian Cancer 2. London: Chapman & Hall, 1992. 371. Parker W, Berek JS. Management of the pelvic mass via operative laparoscopy. In: Soderstrom R, editor. Operative Laparoscopy: The Master's Techniques. Gaithersburg: Aspen Publishers, 1993. 372. Martinez-Maza O, Berek JS. Immunotherapy of ovarian cancer. In: Markman M, Hoskins WJ, editors. Cancer of the Ovary. New York: Raven Press, 1993. 373. Berek JS, Andersen B. Sexual rehabilitation in gynecologic oncology. In: Hoskins W, Perez C, Young RC, editors. Gynecologic Oncology: Principles and Practice. Philadelphia: Lippincott, 1993. 374. Martinez-Maza O, Berek JS. Immunobiology of ovarian cancer. In: Rubin SC, Sutton GP, editors. Ovarian Cancer. McGraw-Hill, Inc., 1993. 375. Martinez-Maza O, Berek JS. Cancer immunology. In: Gynecology and Obstetrics. 376. Berek JS, Dembo A, Ozols RF. Ovarian cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine, Third edition. Philadelphia: Lea & Febiger, 1994. 377. Martinez-Maza O, Berek JS. Immunology of Ovarian Cancer. In: Rubin S, Sutton G, editors. Ovarian Cancer. Saunders, 1994. 378. Martinez-Maza O, Berek JS. Immunology of Gynecologic Disease. In: Dilts PV, Sciarra J, editor. Principles of Obstetrics and Gynecology. Philadelphia: Lippincott, 1994. 379. Berek JS. Nonepithelial ovarian and tubal cancers. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology, Second edition, Williams and Wilkins, 1994. 380. Berek JS. General surgical operations. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology, Second edition, Williams and Wilkins, Publishers, 1994. 381. Parker WH, Berek JS. Management of the pelvic mass by laparoscopy. In: Grochmal S, ed. Minimal Access Gynaecology. Oxford: Radcliffe Medical Press. 1994:187-205. 382. Martinez-Maza O, Berek JS. Immunology and immunotherapy in gynecologic oncology. In: Larry J. Copeland, Ed. Study Guide for Textbook of Gynecology. W.B. Saunders Co, Publishers, 1994. 383. Berek JS, Martinez-Maza O. Molecular and biological factors in the pathogenesis of ovarian 41
  • 42. Jonathan S. Berek, MD, MMS cancer. In: Sharp F, Mason P, Blackett T, Berek JS, eds., Ovarian Cancer 3. Chapman Hall Medical, London, pp 77-88, reproduced from reference 133, 1994 384. Bonavida B, Safrit JT, Morimoto H, Mizutani Y, Yonehara S, Berek JS. Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-alpha/anti-Fas antibody and chemotherapeutic drugs or toxins. In: Sharp F, Mason P, Blackett T, Berek JS, eds., Ovarian Cancer 3. Chapman Hall Medical, London, pp 295-304, 1994. 385. Martinez-Maza O, Berek JS. Immunology and immunotherapy of ovarian cancer. In: Lawton F, editor. The Management of Epithelial Ovarian Cancer. London: British Medical Journal Books, 1995. 386. Berek JS, Hacker NF. Ovary and Fallopian Tubes. In: Haskell CM, editor. Cancer Treatment, Fourth edition. Philadelphia: W.B. Saunders Co, 1995: (portions reproduced from references 50 and 51). 387. Berman ML, Berek JS. Uterine corpus. In: Haskell CM, editor. Cancer Treatment, Third edition. Philadelphia: W.B. Saunders Co., 1995. 388. Hacker NF, Berek JS. Vulva. In: Haskell CM, editor. Cancer Treatment, Fourth edition. Philadelphia: W.B. Saunders Co., 1995. 389. Hacker NF, Berek JS. Vagina. In: Haskell CM, editor. Cancer Treatment, Fourth edition. Philadelphia: W.B. Saunders Co., 1995. 390. Martinez-Maza O, Berek JS. Cancer immunology. In: Lurain J, ed. Gynecologic Oncology. London: BMA Press. l995. 391. Farias-Eisner RP, Walker DL, Berek JS. Gynecologic Cancers. in: Cashciato DA, Lowitz BB, eds. Manual of Clinical Oncology. 2nd ed., Boston: Little, Brown and Co., 1995:200-227. 392. Farias-Eisner R, Casey C, Walker D, Berek JS. Cervical, vaginal and vulvar cancer. In: Abeloff M, Armitage J, Lichter A, Niederhueber J, eds Clinical Oncology. Churchill-Livingston, 1995. 393. Berek JS, Bast RC, Ovarian cancer screening. Proc Am Cancer Soc. National Conference on Gynecologic Cancers, April, 1995, Cancer 76:2092. 394. Berek JS, Hillard PA. Initial assessment and communication. In: Berek JS, Adashi E, Hillard PJA, eds. Novak's Gynecology, 12th edition, 1996. 395. Baker V, Martinez-Maza O, Berek JS. Molecular biology and genetics. In: Berek JS, Adashi E, Hillard PA, eds. Novak's Gynecology, 12th edition, 1996. 396. Berek JS, Fu YS, Hacker NF. Ovarian Cancer. In: Berek JS, Adashi E, Hillard PA, eds. Novak's Gynecology, 12th edition, 1996. 397. Berek JS, Thomas G, Ozols R. Ovarian cancer. Chapter 133, In: Holland JF, Frei E, Bast RC, et al, editors. Oncology: Principles and Practice. Second edition, Philadelphia: Lippincott, 1996. 398. Berek JS, Andersen B. Sexual rehabilitation: surgical and psychological approaches. Chapter 21, In Hoskins WJ, Perez CA, Young RC, eds. Gynecologic Oncology: Principles and Practice. 2nd ed. Philadelphia: Lippincott-Raven, 1996. 42
  • 43. Jonathan S. Berek, MD, MMS 399. Montz FJ, Berek JS. Gynecologic operations. In: Zinner M, ed. Maingots' Abdominal Operations. Philadelphia: Appleton & Lange, 1996. 400. Berek JS. Secondary cytoreductive surgery for epithelial ovarian cancer. In: Gershenson DM, McQuire WP, eds. Controversies in the Management of Ovarian Cancer. New York: Churchill- Livingston. 1996. 401. Gotlieb WH, Berek JS. Le bon usage des marquerurs biologiques. In: Ovarian Cancer. Paris: 1996. 402. Shapter A, Berek JS. Prospects for gene therapy in ovarian cancer. In: Ovarian Cancer 4. Sharp F, Blackett A, Leake R, Berek JS, eds. London: Chapman and Hall Medical, 1996. 403. Eifel P, Berek JS, Thigpen JT. Cancer of the vulva, vagina and cervix. In: DeVita V, Hellman S, Rosenberg S, eds., Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1996. 404. Parker W, Berek JS. Management of the pelvic mass via operative laparoscopy. In: Soderstrom R, editor. Operative Laparoscopy. 2nd ed. New York: Aspen Publishers, 1996. 405. Berek JS. Management of ovarian and cervical malignancies. I In: Expert consultations in gynecologic malignancy, Markman M, Belinson JL, ed, Lippincott-Raven, 1996, pp 7-8, 281-2 393- 4. 406. Berek JS. Ovarian cancer. In Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, 2nd ed., Philadelphia: Saunders, 1996. 407. Berek JS. Trophoblastic disease. In Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, 2nd ed., Philadelphia: Saunders, 1996. 408. Berek JS, Thomas G, Ozols R. Ovarian cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine, Fourth edition. Philadelphia: Lea & Febiger, 1996. 409. Kim YB, Ghosh K, Ainbinder S, Berek JS. Diagnostic and therapeutic advanced in gynecologic oncology: Screening for gynecologic cancer. In: Ozols RF, Gynecologic Oncology, Kluwer Academic Publishers, Boston, 1998, 253-272. 410. Rubin SC, Benjamin I, Berek JS. Secondary cytoreductive surgery. In: Gershenson DM, McGuire WP, Eds. Ovarian Cancer - Controveries in Management. Churchill Livingstone, 1998 411. Berek JS. Ovarian cancer. In: Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, Third Edition. W.B. Saunders Company, Philadelphia,1998 412. Berek JS. Gestational trophoblastic neoplasia. In: Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology, Third Edition. W.B. Saunders Company, Philadelphia,1998 413. Berek JS, Markman M, McGuire WP, Thigpen JT, Ozols RF. Chemotherapy for ovarian cancer. In: New Insights in Gynecology and Obstetrics, Research and Practice, Parthenon Publishing, 1998. 414. Hillard PA, Berek JS. Initial assessment and communication. In: Olive D, Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 43
  • 44. Jonathan S. Berek, MD, MMS 415. Berek JS. Anatomy and embryology. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 416. Cramer DW, Berek JS. Epidemiology for the gynecologist. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 417. Dorigo O, Berek JS. Molecular biology and genetics. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 418. Berek JS. Genitourinary infections and sexually transmitted diseases. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 419. Berek JS, Shapter A. Intraepithelial disease of the cervix, vagina, and vulva. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 420. Berek JS. Early pregnancy loss and ectopic pregnancy. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 421. Berek JS. Hysterectomy. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 422. Young RC, Thomas GM, Berek JS. General principles of cancer therapy. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 423. Shapter AP, Berek JS. Cervical and vaginal cancer. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 424. Bristow RE, Berek JS. Ovarian cancer. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 425. Berek JS. Palliative care and pain management. In: Olive D, Berek JS. Novak’s Gynecology, JS Berek, ed. Study Guide, Williams & Wilkins, Baltimore, 1998. 426. Berek JS, Dorigo O. Oncogenes and growth factors in gynecologic malignancies. In: Hill JA, ed. Cytokines in Reproduction, 1998. 427. Dorigo O, Martinez-Maza O, Berek JS. Immunology and immunotherapy in gynecologic oncology. In: Copeland, L. Ed. Textbook of Gynecology, W.B. Saunders, Publishers, 2nd Edition, 1998. 428. Dorigo O, Berek JS. Biological response modifiers. In: Deppe, G. editor. Chemotherapy of Ovarian Cancer. Alan Liss, Inc., New York, 1999. 429. Dorigo O, Berek JS. Overview - The development of novel treatment strategies for ovarian cancer gene therapy. In: Sharp F, Blackett T, Berek J, Bast R (Eds), Ovarian Cancer 5, Oxford, UK, 1998. 430. Dorigo O, Fakhral H, Shapter A, Berek JS. Interleukin-2 (IL-2) and transforming growth factor beta (TGF-β) antisense gene therapy in a preclinical model system. In: Sharp F, Blackett T, Berek J, Bast R (Eds), Ovarian Cancer 5, Oxford, UK, 1998. 431. Elkas JC, Farias-Eisner R, Berek JS. Cervix, vagina, and vulva. In: Abeloff M, Armitage J, Lichter A, Neiderhueber J, eds Clinical Oncology. Churchill-Livingston, 2nd Edition, 1999 44
  • 45. Jonathan S. Berek, MD, MMS 432. Berek, JS, Markman M, McGuire WP, Thigpen JT, Ozols RF. Chemotherapy for ovarian cancer. In Ottesen B, Tabor A, eds New Insights in Gynecology & Obstetrics Research and Practice. The Parthenon Publishing Group, New York 1998, 211 218 433. Chen LM, Berek JS. Ovarian cancer, in Haskell C, ed, Cancer Treatment , fifth ed., W.B. Saunders, Philadelphia, 2000. 434. Chen LM, Berek JS. Fallopian tube cancer, in Haskell C, ed. Cancer Treatment, fifth ed., W. B. Saunders, Philadelphia, 2000. 435. Elkas J, Berek JS. Vaginal cancer, in Haskell C, ed, Cancer Treatment, fifth edition, W.B. Saunders, Philadelphia, 2000. 436. Holschneider C, Hacker NF, Berek JS. Vulvar cancer, in Haskell C, ed, Cancer Treatment, fifth edition, W.B. Saunders, Philadelphia, 2000. 437. Martinez-Maza O, Berek JS. Immunology and biologic therapy, in Berek JS, Hacker NF, Practical Gynecologic Oncology, third edition, Lippincott Williams and Wilkins, Philadelphia, 2000. 438. Berek JS, Hacker NF. Epithelial ovarian cancer, in Berek JS, Hacker NF, Practical Gynecologic Oncology, third edition, Lippincott Williams and Wilkins, Philadelphia, 2000. 439. Berek JS, Hacker NF. Non-epithelial ovarian cancer, in Berek JS, Hacker NF, Practical Gynecologic Oncology, third edition, Lippincott Williams and Wilkins, Philadelphia, 2000. 440. Berek JS. General surgical operations, in Berek JS, Hacker NF, Practical Gynecologic Oncology, third edition, Lippincott Williams and Wilkins, Philadelphia, 2000. 441. Elkas JC, Dorigo O, Berek JS. Intraperitoneal biologic therapy in ovarian cancer. In: Markman M, editor. Regional Chemotherapy: Clinical Research and Practice, Humana Press, 2000, pgs 193- 211. 442. Berek JS, Ozols R. Summary of the ovarian cancer trials of the Gynecologic Oncology Group. In: Sharp F, Jacobs I, Blackett A, editors. Ovarian Cancer 6, Blackwell Scientific Publishers, Malden, MA, 2000. 443. Berek JS, Thomas G, Ozols R. Ovarian cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine, Fifth edition. Philadelphia: Lea & Febiger, 2000. 444. Farias-Eisner RP, Berek JS. Gynecologic cancers. Handbook of Cancer Therapy. Cashaito D., ed., Little, Brown, Co. Boston, 2000. 445. Berek JS. Ovarian cancer. Berek, JS, In Novak’s Gynecology, thirteenth edition, Lippincott Williams and Wilkins, Philadelphia, 2002. 446. Baker V, Martinez-Maza O, Berek JS. Biology and genetics. In Berek, JS, Novak’s Gynecology, thirteenth edition, Lippincott Williams and Wilkins, Philadelphia, 2002. 447. Holschneider C, Berek JS. Vulvar cancer. In Berek, JS, Novak’s Gynecology, thirteenth edition, Lippincott Williams and Wilkins, Philadelphia, 2002. 448. Berek JS, Hillard P. Initial assessment and communication. In Berek, JS, Novak’s Gynecology, 45
  • 46. Jonathan S. Berek, MD, MMS thirteenth edition, Lippincott Williams and Wilkins, Philadelphia, 2002. 449. Berek JS, Bast RC. Ovarian cancer. Chapter 118. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine, Sixth edition. Hamilton: Decker, 2003. 450. Berek JS. Gynecologic cancers. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine Review, Sixth edition. Hamilton: Decker, 2003. 451. Berek JS. Ovarian cancer. In: Hacker NF, Moore JG, Gambone J, eds. Essentials of Obstetrics and Gynecology, Fourth Edition. Elsevier Science, W.B. Saunders Company, New York, 2003. 452. Berek JS. Gestational trophoblastic neoplasia. In: Hacker NF, Moore JG, Gambone J, eds. Essentials of Obstetrics and Gynecology, Fourth Edition. Elsevier Science, W.B. Saunders Company, New York, 2003. 453. Hillard PA, Berek JS. Initial assessment and communication. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 454. Berek JS. Anatomy and embryology. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 455. Cramer DW, Berek JS. Epidemiology for the gynecologist. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 456. Dorigo O, Berek JS. Molecular biology and genetics. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 457. Berek JS. Genitourinary infections and sexually transmitted diseases. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 458. Berek JS, Shapter A. Intraepithelial disease of the cervix, vagina, and vulva. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 459. Berek JS. Early pregnancy loss and ectopic pregnancy. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 460. Berek JS. Hysterectomy. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 461. Shapter AP, Berek JS. Cervical and vaginal cancer. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 462. Bristow RE, Berek JS. Ovarian cancer. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 463. Berek JS. Palliative care and pain management. In: Berek JS Novak's Gynecology, JS Berek, ed. Study Guide, Second Edition, Lippincott Williams & Wilkins, Philadelphia, 2002. 464. Memarzadeh S, Farias-Eisner RP, Berek JS. Gynecologic Cancers. in: Cashciato DA, Lowitz BB, eds. Manual of Clinical Oncology. 3rd ed., Boston: Little, Brown and Co., 2003 46
  • 47. Jonathan S. Berek, MD, MMS 465. Martinez-Maza O, Berek JS. Cancer immunology. In: Dilts PV, Sciarra J, editor. Principles of Obstetrics and Gynecology. Philadelphia: Lippincott, 2003. 466. Martinez-Maza O, Berek JS. Immunology and biologic therapy, in Berek JS, Hacker NF, Practical Gynecologic Oncology, fourth edition, Lippincott Williams and Wilkins, Philadelphia, 2005. 467. Berek JS, Hacker NF. Epithelial ovarian cancer, in Berek JS, Hacker NF, Practical Gynecologic Oncology, fourth edition, Lippincott Williams and Wilkins, Philadelphia, 2005. 468. Berek JS, Hacker NF. Non-epithelial ovarian cancer, in Berek JS, Hacker NF, Practical Gynecologic Oncology, fourth edition, Lippincott Williams and Wilkins, Philadelphia, 2005. 469. Berek JS. General surgical operations, in Berek JS, Hacker NF, Practical Gynecologic Oncology, fourth edition, Lippincott Williams and Wilkins, Philadelphia, 2005. 470. Hatch K, Berek JS. Pelvic Exenteration, in Berek JS, Hacker NF, Practical Gynecologic Oncology, fourth edition, Lippincott Williams and Wilkins, Philadelphia, 2005. 471. Berek JS, Hillard PA. Initial assessment and communication. Berek JS. Berek & Novak ’s Gynecology. Fourteenth edition. Lippincott Williams and Wilkins, Philadelphia 2006. 472. Dorigo O, Martinez-Maza, Berek JS. Molecular biology and genetics. Berek JS. Berek & Novak’s Gynecology. Fourteenth edition. Lippincott Williams and Wilkins, Philadelphia 2006. 473. Berek JS, Natarajan S. Ovarian cancer. Berek JS. Berek & Novak’s Gynecology. Fourteenth edition. Lippincott Williams and Wilkins, Philadelphia 2006. 474. Hatch K, Berek JS. Intraepithelial disease of the cervix, vagina and vulva. Berek JS. Berek & Novak’s Gynecology. Fourteenth edition. Lippincott Williams and Wilkins, Philadelphia 2006. 475. Holschneider C, Berek JS. Berek JS Berek & Novak’s Gynecology. Fourteenth edition. Lippincott Williams and Wilkins, Philadelphia 2006. 47
  • 48. Jonathan S. Berek, MD, MMS INVITED LECTURES AT NATIONAL & INTERNATIONAL MEETINGS 1. Berek JS, Griffiths CT, Leventhal J: Laparoscopy for second-look ovarian cancer. Presented at the 10th Annual Meeting of the Society of Gynecologic Oncologists, Marco Island, Florida, January 1979 2. Berek JS, Castaldo TW, Hacker NF, Petrilli ES, Lagasse LD, Moore JG: Adenocarcinoma of the uterine cervix. Presented at the 8th Annual Meeting of the Western Association of Gynecologic Oncologists, Lake Tahoe, Nevada, May 1980 3. Berek JS, Hacker NF, Leuchter RS, Lagasse LD, Byron RL: Urological operations during cytoreductive surgery for ovarian cancer. Presented at the 12th Annual Meeting of the Society of Gynecologic Oncologists, Marco Island, Florida, January, 1981 4. Berek JS, Lagasse LD, Hacker NF, Leuchter RS: Levator ani transposition for anal incontinence. Presented at the 9th Annual Meeting of the Western Association of Gynecologic Oncologists, Napa, California, May 27-30, 1981 5. Ford LC, Berek JS, Lagasse LD, Heins Y, Leuchter RS, Hacker NF, DeLange FJ: Estrogen and progesterone receptors in ovarian neoplasms. Presented at the 9th Annual Meeting of the Western Association of Gynecologic Oncologists, Napa, California, May 27-30, 1981 6. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Presented at the 13th Annual Meeting of the Society of Gynecologic Oncologists, Marco Island, Florida, January, 1982 7. Berek JS, Zighelboim J, Hacker NF, Bast RC, Chamorro T, Lagasse LD: Augmentation of natural killer (NK) and antibody dependent cell mediated cytotoxicity (ADCC) by Corynebacterium parvum in peritoneal effluents of patients with ovarian cancer. Presented at the Annual Meeting of the Society for Gynecologic Investigation, Dallas, Texas, March, 1982 8. Berek JS, Hacker NF, Lagasse LD, Smith ML: Delayed vaginal reconstruction in the fibrotic pelvis: Results after radiation or previous reconstructive attempts. Presented at the 10th Annual Meeting of Western Association of Gynecologic Oncologists, Santa FE, New Mexico, May 1982 9. Berek JS, Zighelboim J, Hacker NF, Bast RC, Chamorro T, Lagasse LD: Natural killer (NK) lymphocytes and antibody dependent cell-mediated cytotoxicity (ADCC) in the peritoneal effluents of advanced ovarian cancer patients treated with intraperitoneal Corynebacterium parvum. Presented at the 10th Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Fe, New Mexico, May 1982 10. Berek JS; Techniques of vaginal reconstruction. Symposium on reconstructive surgery. Thirteenth International Cancer Congress, Seattle, Washington, September 15, 1982 11. Berek JS, Hacker NF, Lichtenstein A, Zighelboim J, Cantrell J, Lagasse LD: Tumor rejection in the peritoneal cavity of a murine ovarian cancer model using immunotherapy with biologic response modifiers. Presented at the 14th Annual Meeting of the Society of Gynecologic Oncologists, Scottsdale, Arizona, February 7, 1983 12. Berek JS, Hacker NF, Lagasse LD, Resnick B, Poth T, Nieberg RK: Second-look laparotomy in epithelial ovarian cancer: Variables predictive of disease status. Proceedings of the Eleventh Annual Meeting of the Western Association of Gynecologic Oncologists, Colorado Springs, Colorado, May 1983 48
  • 49. Jonathan S. Berek, MD, MMS 13. Berek JS, Hacker NF, Lagasse LD, Resnick B, Poth T, Nieberg RK, Elashoff RM: Second-look laparotomy for epithelial ovarian cancer. Proceedings of the Nineteenth Annual Meeting of the American Society of Clinical Oncology, ASCO Abstract C-613, San Diego, California, May 1983 14. Berek JS, Hacker NF, Lagasse LD, Resnick B, Poth T, Nieberg RK: Second-look laparotomy in epithelial ovarian cancer: Variables predictive of disease status. Proceedings of the Second Annual International Symposium on Gynecologic Oncology, Edinburgh, Scotland, September 1983 15. Berek JS, Moderator, Third Scientific Session, The Eleventh Annual Meeting of the Western Association of Gynecologic Oncologists, Colorado Springs, Colorado, May 1983 16. Berek JS: An update on the immunobiology of the peritoneal cavity and regional immunomodulators in ovarian cancer. Presented at the Scientific Session of the Semi-Annual Meeting of the Gynecologic Oncology Group, National Cancer Institute, Denver, Colorado, July 1983 17. Berek JS, Hacker NF, Lagasse LD: Rectosigmoid colectomy and reanastamosis to facilitate resection of primary and recurrent pelvic cancer. Presented to the Thirty-Third Annual Meeting of the Society of Pelvic Surgeons, Philadelphia, Pennsylvania, November 1983 18. Berek JS, Hacker NF, Fu YS, Sokale J, Leuchter RS, Lagasse LD: Adenocarcinoma of the uterine cervix: the influence of lesion size and grade on lymph node metastasis and prognosis. Presented at the Fifteenth Annual Meeting of the Society of Gynecologic Oncologists, Miami, Florida, February 1984 19. Berek JS: Treatment of ovarian cancer: secondary operative and therapeutic approaches. UCLA Winter Oncology Conference, Santa Monica, California, March 1984 20. Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Nieberg RK, Lagasse LD, Zighelboim J: Immunotherapy with biochemically dissociated fractions of propionibacterium acnes in a murine ovarian cancer model. Presented at the Thirty-First Annual meeting of the Society for Gynecologic Investigation, San Francisco, California, March 1984 21. Berek JS, Cantrell JL, Lichtenstein AK, Hacker NF, Knox RM, Zighelboim J: Immunotherapy in murine ovarian cancer model. Presented at the Seventy-Fifth annual meeting of the American Association for Cancer Research, Toronto, Canada, May 1984 22. Berek JS, Hacker NF, Fu YS, Sokale J, Leuchter RS, Lagasse LD: Adenocarcinoma of the uterine cervix: the influence of lesion size and grade on lymph node metastasis and prognosis. Presented at the Annual Meeting of the American College of Obstetrics and Gynecology, San Francisco, California, May 1984 23. Berek JS, Lichtenstein AK, Cantrell JL, et al: Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Presented at the Thirty-Second Annual Meeting of the Society for Gynecologic Investigation, Phoenix, Arizona, March 1985 24. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Presented at the Annual Meeting of the Society of Gynecologic Oncologists, Miami, Florida, February 1985 49
  • 50. Jonathan S. Berek, MD, MMS 25. Berek JS, Jung TS, Lichtenstein A, et al: Systemic and intraperitoneal(ip) immunological and pharmacokinetic data in patients treated with ip recombinant interferon for persistent ovarian cancer. Presented at the Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, California, June 1985 26. Berek JS: Staging and second-look operations in ovarian cancer. Presented at the Thirty-Third Annual Meeting of the American College of Obstetricians and Gynecologists. Washington, D.C., May 1985 27. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal immunotherapy of human ovarian carcinoma with recombinant interferon: a phase I toxicity/immunopharmacology study. Presented at the twenty-first annual meeting of the American Society of Clinical Oncologists, Houston, Texas, May 1985 28. Berek JS, et al: Symposium: The treatment of early stage vulvar carcinoma. Presented at the Western Association of Gynecologic Oncologists, San Diego, CA, May 1985 29. Berek JS, et al: Symposium: The treatment of advanced vulvar carcinoma. Presented at the Western Association of Gynecologic Oncologists, San Diego, CA, May 1985 30. Berek JS: The surgical staging of cervical carcinoma. Presented at the Third International Conference on Gynecologic Oncology, the Netherlands, June 1985 31. Berek JS: Salvage therapy in ovarian cancer. Presented at the Third International Conference on Gynecologic Oncology, the Netherlands, June 1985 32. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal interferon in ovarian cancer. Presented at the Third International Conference of Clinical Oncology, Stockholm, Sweden, June 1985 33. Berek JS: Reconstructive pelvic surgery simultaneous with pelvic exenteration. Presented at the 71st Annual Clinical Congress, Chicago, October, 1985 34. Berek JS: Cytoreductive surgery in ovarian cancer. Presented at the 71st Annual Clinical Congress, Chicago, October, 1985 35. Berek JS: Regional biologic response modifiers in ovarian cancer. Presented at the Scientific Session of the Gynecologic Oncology Group, Anaheim, CA, February, 1986 36. Berek JS: Intraperitoneal therapy in ovarian cancer. Presented at the National Convention of the Society of Gynecologic Nurse Oncologists, Anaheim, CA, February, 1986 37. Berek JS, Knapp RC, Malkasian GD, Lavin DT, Whitney C, Niloff JM, Bast RC: CA-125 serum levels correlated with second-look operations among ovarian cancer patients. Presented at the Seventeenth Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, February 1986 38. Berek JS, Lichtenstein AK, Zighelboim J: Tumor dormancy: the establishment of a model in a murine ovarian teratocarcinoma system. Presented at the Thirty-Third Annual Meeting of the Society of Gynecologic Investigation, Toronto, Canada March, 1986 39. Berek JS: Intraperitoneal therapy in ovarian cancer. Symposium on Gynecologic Cancer. Princess Margaret Hospital, University of Toronto, Toronto, Canada March, 1986 50
  • 51. Jonathan S. Berek, MD, MMS 40. Berek JS: Pelvic reconstruction. Symposium on gynecologic cancer. Princess Margaret Hospital, University of Toronto, Toronto, Canada, March 1986 41. Berek JS: Moderator, General Session on Gynecologic Cancer, Annual Meeting the American Radium Society, San Francisco, CA, April 1986 42. Berek JS: Gynecologic Cancer, Meet-The-Professor Workshop, Annual Meeting of the American Radium Society, San Francisco, CA, April 1986 43. Berek JS: Intraperitoneal interferon in ovarian cancer. Presented at the National Symposium on Interferon Research. Seabrook Conference, Charleston, South Carolina, April 1986 44. Berek JS: Immunodiagnosis of ovarian cancer. Post-graduate course, Update in Gynecologic Oncology, presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, New Orleans, Louisiana, May 1986 45. Berek JS: Adenocarcinoma of the cervix. Post-graduate course, Update in Gynecologic Oncology, presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA, May 1986 46. Berek JS: Borderline Tumors of the Ovary. Post-graduate course, Update in Gynecologic Oncology, presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA, May 1986 47. Berek JS: Chemotherapy of Ovarian Cancer. Post-graduate course, Update in Gynecologic Oncology, presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA, May 1986 48. Berek JS: Treatment of Germ Cell Tumors of the Ovary. Post-graduate course, Update in Gynecologic Oncology, presented at the Annual Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA, May 1986 49. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC: CA-125 serum levels correlated with second-look operations among ovarian cancer patients. Presented at the Twenty-second Annual Meeting of the American Society of Clinical Oncologists, Los Angeles, CA, May 1986 50. Berek JS: The use of the CO2 laser for treatment of vulvar disease. Presented at the Annual Meeting of the American College of Surgeons, New Orleans, LA, October l986 51. Berek JS: Intraperitoneal Immunotherapy of Ovarian Cancer, Annual Oncology Review: Treatment Strategies, l986. The Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, November l986 52. Berek JS: Surgery in Ovarian Cancer, Symposium, Massachusetts General Hospital, Boston, MA, November l986 53. Berek JS: Intraperitoneal Immunotherapy of Ovarian Cancer, Johns Hopkins Medical School, Hematology/Oncology Lecture, Baltimore, MD, November 1986 54. Berek JS: Lymphocyte activation with interleukin-2 in patients with ovarian carcinoma. Presented at the annual meeting of the Society of Gynecologic Oncologists, Miami, FL, February 51
  • 52. Jonathan S. Berek, MD, MMS 1987 55. Berek JS, Knox, RM: Intraperitoneal cytosine arabinoside given prior to or with cisplatin results in synergy of survival in a murine ovarian carcinoma model. Presented at the annual meeting of the Society of Gynecologic Investigation, Atlanta, GA, March 1987 56. Berek JS: Intraperitoneal immunomodulation in ovarian carcinoma with cytokines. Presented at the American Cancer Society Science Writer's Seminar, San Diego, CA, March 1987 57. Berek JS: Intraperitoneal therapies in ovarian cancer. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American Gynecological Club, Los Angeles, CA, March 1987 58. Berek JS: Immunodiagnosis and immunotherapy of gynecologic malignancies. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 59. Berek JS: Chemotherapy of ovarian cancer. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 60. Berek JS: Hormonal and chemotherapy of endometrial cancer. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 61. Berek JS: Germ cell tumors of the ovary. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 62. Berek JS: Borderline tumors of the ovary. Post-graduate course: Gynecologic Oncology. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 63. Berek JS: Second-look operations in ovarian cancer. Presented at the annual meeting of the American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1987 64. Berek JS: Evaluation of preinvasive neoplasia of the female genital tract. Presented at the annual meeting of the Planned Parenthood, San Francisco, CA, May 1987 65. Berek JS: Immunotherapy of ovarian cancer. Presented at the annual meeting of the Western Association of Gynecologic Oncologists, Tucson, AZ, May 1987 66. Berek JS: Immunotherapy of ovarian cancer. Presented at the annual Scientific Session of the Southwest Oncology Group (SWOG), Phoenix, AZ, September 1986 67. Berek JS: Intraperitoneal biologic response modifiers in ovarian cancer. Presented at the annual meeting of the European Organization for the Research and Treatment of Cancer (EORTC), Brescia, Italy, June 1987 68. Berek JS: Analysis of protocol design of the ovarian cancer trials of the Gynecologic Oncology Group (GOG). Presented at the annual meeting of the European Organization for the Research and Treatment of Cancer (EORTC), Brescia, Italy, June 1987 52
  • 53. Jonathan S. Berek, MD, MMS 69. Berek JS: Immunotherapy of gynecologic malignancies. Harvard School, Massachusetts General Hospital, Symposium on Gynecologic Cancer, Boston, MA, Sept 1987 70. Berek JS: Second-look laparotomy in ovarian cancer. Harvard Medical School Massachusetts General Hospital, Symposium on Gynecologic Cancer, Boston, MA, Sept 1987 71. Berek JS: Immunotherapy of ovarian cancer. Symposium. International Society of Gynecologic Oncology, Amsterdam, Oct 1987 72. Berek JS: Intraperitoneal therapy in ovarian cancer. International Society of Gynecologic Oncology, Amsterdam, Oct 1987 73. Berek JS: Tumor infiltrating lymphocytes in ovarian cancer, discussion, Society of Gynecologic Oncologists, Miami, FL, Feb 1988 74. Berek JS: Moderator, Sixth Scientific Session, Society of Gynecologic, Oncologists, Miami, FL, Feb 1988 75. Berek JS: Moderator, Immunology in Obstetrics and Gynecology, Society of Gynecologic Investigation, Baltimore, MD, March 1988 76. Berek JS: Intraperitoneal cisplatin plus alpha interferon in minimal residual ovarian cancer. Second International Conference on Intracavity Therapy, San Diego, CA, Feb 1988 77. Berek JS: Intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. Second International Conference on Intracavity Therapy, San Diego, CA, Feb 1988 78. Berek JS: Chemotherapy for ovarian cancer. American Radium Society, Seattle, WA, April 1988 79. Berek JS: Borderline tumors of the ovary. Postgraduate course in Gynecologic Cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 80. Berek JS: Germ cell tumors of the ovary. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 81. Berek JS: Immunodiagnosis and immune monitoring in ovarian cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 82. Berek JS: Hormonal therapy and chemotherapy for endometrial cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 83. Berek JS: Chemotherapy for ovarian cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 84. Berek JS: Preinvasive and early invasive vulvar disease. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Boston, MA, May 1988 85. Berek JS: Intraperitoneal cisplatin and alpha-interferon in ovarian cancer. American Society of Clinical Oncologists, New Orleans, LA, May 1988 86. Berek JS: Intraperitoneal cisplatin and alpha-interferon in ovarian cancer. Western Association 53
  • 54. Jonathan S. Berek, MD, MMS of Gynecologic Oncologists, Jackson Hole, WY, June 1988 87. Berek JS: Intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian tumor model. Western Association of Gynecologic Oncologists, Jackson Hole, WY, June 1988 88. Berek JS: Symposium: Intraperitoneal therapy in ovarian cancer. Western Association of Gynecologic Oncologists, Jackson Hole, WY, June 1988 89. Berek JS: Recent progress in gynecologic cancer. Dallas Obstetrical and Gynecologic Society, Dallas, TX, August 1988 90. Berek JS: Surgery for ovarian cancer. Alabama Society of Clinical Oncology, Birmingham, AL, August 1988 91. Berek JS: Discussant: A prospective randomized trial of topical interferon (IFN) gels for the treatment of vulvar intraepithelial neoplasia III (VIN III), Spirtos NM, Society of Gynecologic Oncologists, Maui, Hawaii, February 1989 92. Berek JS: The biology of neoplasia: Gynecologic malignancies. Society for Gynecologic Investigation, San Diego, California, March 1989 93. Berek JS: The immunological control of ovarian cancer. The Helene Harris Memorial Trust Second International Forum on Ovarian Cancer, Graz, Austria, March 1989 94. Berek JS: Evaluation and management of invasive vulvar cancer. Post-graduate course: American College of Obstetricians and Gynecologists, Atlanta, Georgia, May 1989 95. Berek JS: Chemotherapy in advanced epithelial ovarian cancer. Post-graduate course: American College of Obstetricians and Gynecologists, Atlanta, Georgia, May 1989 96. Berek JS: Rationale and technique for debulking ovarian cancer. Post-graduate course: American College of Obstetricians and Gynecologists, Atlanta, Georgia, May 1989 97. Berek JS: Antigens of gynecologic cancers. Post-graduate course: American College of Obstetricians and Gynecologists, Atlanta, Georgia, May 1989 98. Berek JS: Intraperitoneal immunotherapy. Scientific session. Gynecologic Oncology Group, Birmingham, Alabama, July 1989 99. Berek JS: Modifications in the treatment of invasive vulvar cancer. Baker-Channing Society. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, September, 1989 100. Berek JS: Monoclonal antibodies in gynecologic oncology: applications and future directions. International Gynecologic Cancer Society, Toronto, Ontario, Canada, October 1989 101. Berek JS: Intraepithelial neoplasia of the vulva. Association of Reproductive Health Professionals, San Diego, October 1989 102. Berek JS: Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin and doxorubicin in ovarian cancer cells. Society of Gynecologic Oncologists, San Francisco, CA, February 1990 103. Berek JS: Surgical-pathologic variables predictive of local recurrence in squamous cell 54
  • 55. Jonathan S. Berek, MD, MMS carcinoma of the vulva. Society of Gynecologic Oncologists, San Francisco, CA, February 1990 104. Berek JS: Interleukin-6 is constituitively produced by ovarian cancer cells. Society for Gynecologic Investigation. St. Louis, March 1990 105. Berek JS: Ovarian Cancer. American Society of Clinical Oncologists. Washington, D.C., May 1990 106. Berek JS: Postgraduate course in gynecologic oncology. American College of Obstetricians and Gynecologists. San Francisco, May 1990 107. Berek JS: Serum levels of interleukin-6 correlate with disease status in epithelial ovarian cancer. American Gynecological and Obstetrical Society. Hot Springs, Virginia, September 1990 108. Berek JS: Screening for ovarian cancer. Board of Scientific Advisors. National Cancer Institute. Bethesda, Maryland, October 1990 109. Berek JS: Ovarian cancer. American Society of Clinical Oncologists. Anaheim, CA, October 1990 110. Berek JS: Diagnosis and screening for malignancy in the female patient. Symposium on Women's Health Care. Laguna Niguel, CA, January 1991 111. Berek JS: Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced vulvar cancer. Society of Gynecologic Oncologists. Orlando, FL, February 1991 112. Johnson M, Kaldi K, Watson JM, Martinez-Maza O, Berek JS: Immunosuppressive effect of a soluble factor in ascites against interleukin-6 induced proliferation of ovarian carcinoma cells. Society of Gynecologic Oncologists. San Antonio, Tx, March 1991 113. Berek JS, Watson JM, Martinez-Maza: The role of interleukin-6 in ovarian cancer. Third Biennial International Forum on Ovarian Cancer. Helene Harris Memorial Trust. Charleston, S.C., April 1991 114. Berek JS, Markman M: Intraperitoneal cisplatin and alpha interferon in epithelial ovarian cancer. Third Biennial International Forum on Ovarian Cancer. Helene Harris Memorial Trust. Charleston, S.C., April 1991 115. Berek JS: Surgery for endometrial cancer, Staging of ovarian cancer, CA 125 in ovarian cancer. Royal Hospital for Women. Symposium on Gynaecologic Oncology. Leura, Australia, April 1991 116. Berek JS: CA 125 in ovarian cancer, Chemotherapy of ovarian cancer, Cytoreductive surgery for ovarian cancer, Contemporary therapy of vulvar cancer. American College of Obstetricians and Gynecologists. 120 Postgraduate Course. Annual Clinical Meeting, New Orleans, LA, May 1991 117. Stenson R, Watson JM, Martinez-Maza O, Berek JS: Interleukin 6 and her2/neu expression and growth regulation of ovarian cancer cell lines. Western Association of Gynecologic Oncologists. Newport, CA, June 1991 118. Berek JS: Surgery for ovarian, cervical, uterine cancer, and CA 125 in ovarian cancer. European Oncology Postgraduate Course. Orta, San Guilio, Italy, June 1991 55
  • 56. Jonathan S. Berek, MD, MMS 119. Johnson MT, Watson JM, Berek JS, Martinez-Maza O: Soluble immunosuppressive factor mitigates natural killer cell-mediated cytotoxicity in ovarian cancer in vitro. International Gynecologic Cancer Society, Biannual Meeting, Cairns, Australia, September 24-29, 1991 120. Stenson R, Watson J, Berek JS, Martinez-Maza O: Inerleukin 6 and her2/neu expression and growth regulation in epithelial ovarian cancer cell lines. International Gynecologic Cancer Society, Biannual Meeting, Cairns, Australia, September 24-29, 1991 121. Berek JS, Kreinenberg R, Mertlesmann M, Kaufmann M, Neijt J: New concepts in the treatment of ovarian cancer: oncogenes, growth factors, cytokines and monoclonal antibodies. Consensus Conference on Ovarian Cancer, Freiburg, Germany, October 17-20, 1991 122. Berek JS, Hacker NF, Pfleiderer H, Meerpohl H, Kacinski B, Einhorn N, Neijt J: Consensus report on the management of ovarian cancer. Consensus Conference on Ovarian Cancer, Freiburg, Germany, October 17-20, 1991 123. Berek JS, Dravecky E: The management of the resident with a behavioral problem. Association of Professors of Obstetrics and Gynecology/Council on Residency Education, Annual Meeting, Orlando, Florida, March 4-7, 1992 124. Watson JM, Berek JS, Martinez-Maza O: Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotide-mediated IL-6 translation arrest. Society of Gynecologic Oncologists/Society for Gynecologic Investigation Joint Plenary Session, Annual Meetings, San Antonio, Texas, March 14-21, 1992 125. Berek JS: Telomere reduction in endometrial adenocarcinoma. Society of Gynecologic Oncologists/Society for Gynecologic Investigation Joint Plenary Session, Annual Meetings, San Antonio, Texas, March 14-21, 1992 126. Johnson MT, Watson JM, Berek JS, Martinez-Maza O: Interleukin 6 induces resistance of ovarian tumors to natural killer cell-mediated cytotoxicity. Society for Gynecologic Investigation. Annual Meeting, San Antonio, Texas, March 18-21, 1992 127. Berek JS: Review of growth factors, cytokines and immunoproteins in ovarian cancer. Symposium of the early detection and diagnosis of ovarian cancer. National Cancer Institute, Annapolis, Maryland, April 13, 1992. 128. Berek JS: Early detection and screening for ovarian cancer. Symposium of the early detection and diagnosis of ovarian cancer. National Cancer Institute, Annapolis, Maryland, April 13, 1992. 129. Martinez-Maza O, Berek JS: Interleukin 6 and 10 in ovarian cancer. Symposium of the early detection and diagnosis of ovarian cancer. National Cancer Institute, Annapolis, Maryland, April 13, 1992. 130. Farias-Eisner R, Oliviera M, Teng F, Berek JS: The influence of the tumor distribution, number, maximum size and the extent of carcinomatosis after optimal primary cytoreductive surgery for epithelial ovarian cancer. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 131. Johnson MT, Gotlieb WH, Rabbi M, Martinez-Maza O, Berek JS: Induction of cisplatin resistance by interleukin 6 and dexamethasone. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 56
  • 57. Jonathan S. Berek, MD, MMS 132. Johnson M, Watson JM, Berek JS, Martinez-Maza O: Autocrine induction of tumor resistance to natural killer cell-mediated apoptosis by interleukin 6. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 133. Farias-Eisner R, Cirisano F, Grouse D, Karlan B, Leuchter R, Futoran R, Lagasse LD, Berek JS: Conservative and individualized surgery in early vulvar cancer: the treatment of choice for stage I and II disease. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 134. Farias-Eisner R, Cirasano F, Karlan B, Leuchter R, Futoran R, Lagasse LD, Berek JS: Adjuvant radiation therapy after radical hysterectomy for stage Ib cervical cancer. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 135. Berek JS, Gotlieb WH, Johnson MT, Watson JM, Martinez-Maza O: Relationship between the p53 tumor suppressor gene, tumor necrosis factor and the induction of apoptosis in ovarian cancer cell lines. Western Association of Gynecologic Oncologists, Annual Meeting, June 1992 136. Berek JS: The growth regulation of ovarian cancer. Baker-Channing Society, Harvard Medical School, Annual Meeting, November 1992 137. Berek JS: Endometrial Cancer. Los Angeles Radiation Society. January 1993 138. Berek JS: Molecular biology of ovarian cancer. Israel Cancer Society. Jerusalem, Israel, March 1993 139. Berek JS: Contemporary management of ovarian and endometrial cancer. Royal Hospital for Women, Sydney, Postgraduate Course. Leura, Australia, April 1993 140. Casey AC, Watson JM, Berek JS, Martinez-Maza O: The effect of T-cell derived cytokines on ovarian cancer cell proliferation and IL-6 production. Western Association of Gynecologic Oncologists, Annual Meeting, May 1993 141. Berek JS: Cytokines, growth factors and oncogenes in the growth regulation of ovarian cancer. Helene Harris Memorial Trust, 4th Biennial International Forum on Ovarian Cancer, Toronto, Canada, May 1993 142. Berek JS: Molecular and biologic factors in the pathogenesis of ovarian cancer. Ovarian Consensus Conference, Copenhagen, Denmark, June 1993 143. Berek JS: Tumor suppressor genes, cytokines and apoptosis in ovarian cancer. American Gynecologic and Obstetric Society, Laguna Niguel, CA, September 1993 144. Berek JS: The growth regulation of ovarian cancer. New York Obstetrical Society, Yale Club, New York, October 1993 145. Parker WH, Berek JS: Management of selected adnexal masses in postmenopausal women by operative laparoscopy - a multicentered study. The World Congress of Gynecologic Endoscopy, The American Association of Gynecologic Laparoscopists 22nd Annual Meeting, San Francisco, November 1993 146. Berek JS: Ovarian and vulvar cancer. University of California, San Francisco, Postgraduate Course, October 1993 57
  • 58. Jonathan S. Berek, MD, MMS 147. Berek JS: Basic Science Session, Moderator. Society of Gynecologic Oncologists, Orlando, FL, February 1994 148. Berek JS: Molecular biology of ovarian cancer. Society of Gynecologic Investigation. Chicago, IL, March 1994 149. Berek JS: Ovarian cancer. Visiting Professor, University of Texas, Houston, TX, May 1994 150. Berek JS: The role of lymphadenectomy for the treatment of invasive cervical cancer. Alon Dembo Symposium. Toronto, Canada, September 1994 151. Berek JS: The contemporary management of ovarian cancer. The Conrad Collins Lecture. Tulane Obstetrics and Gynecologic Society, New Orleans, LA, October 1994 152. Berek JS: Prospects for gene therapy in ovarian cancer. Helene Harris Memorial Trust, Royal College of Obstetricians and Gynaecologists, London, England, October 1994 153. Berek JS: Prospects for gene therapy in ovarian cancer. Molecular biology symposium. Society of Gynecologic Oncologists, San Francisco, CA, February 1995 154. Kim YB, Berek JS, Martinez-Maza O, Satyaswaroop PG: Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Society of Gynecologic Oncologists. San Francisco, CA, February 1995. 155. Berek JS, Bast RC Jr. Ovarian cancer screening. National Conference on Gynecologic Cancers. American Cancer Society. Washington, DC, April 1995. 156. Berek JS, Bast RC Jr., Kavanagh JJ, Shpall EJ. Advanced ovarian cancer: new drugs and surgery. American Society of Clinical Oncologists, 31st annual meeting. Los Angeles, May 1995. 157. Berek JS. Meet the Professor. American College of Obstetricians and Gynecologists. 43rd annual clinical meeting. San Francisco, May 1995. 158. Berek JS. Richard TeLinde Lecture. Johns Hopkins University School of Medicine. Baltimore, October 1995. 159. Berek JS. Endometrial Cancer. Lehigh Valley Regional Cancer Symposium. October 1995. 160. Berek JS. Diagnosis and management of uterine malignancies. UCLA -wide Obstetrics and Gynecology review course. Los Angeles, October 1995 161. Berek JS. Contemporary management of cancer of the ovary, vulva, endometrium. Molecular biology and genetics of ovarian cancer. Argentina Association of Gynecologic Oncologists. Cordoba, Argentina, December 1995. 162. Berek JS. Gene therapy of ovarian cancer with HSV-thymidine kinase suicide gene transfection. Plenary session discussant. Society of Gynecologic Investigation. 43rd annual meeting. Philadelphia, March 1996. 163. Berek JS. Taxol and platinum chemotherapy in ovarian cancer. The Helene Harris International Forum on Ovarian Cancer. Royal College of Obstetricians and Gynaecologists. London, March 1996. 58
  • 59. Jonathan S. Berek, MD, MMS 164. Berek JS. New strategies for the molecular-based therapy of ovarian cancer. American Radium Society. San Francisco. March 1996. 165. Berek JS. Moderator: gynecologic malignancies. American Radium Society. San Francisco. March 1996. 166. Berek JS. The management of ASCUS on Pap tests. American College of Obstetricians and Gynecologists. Annual Clinical Meeting. Denver. April 1996. 167. Berek JS. The molecular genetics of ovarian cancer. The Zeneca Lecture. British Gynaecological Cancer Society, Sheffield, United Kingdom, May 1996 168. Dorigo O, Berek JS. The development of a tumor specific vaccine in a murine ovarian cancer model. Western Association of Gynecologic Oncologists, San Diego, May 1996 169. Berek JS. The molecular genetics of ovarian cancer. The First Annual Saul Gusberg Lecture, Mt. Sinai University College of Medicine, New York, June 1996 170. Berek JS. The molecular biology, immunobiology and prospects for gene therapy in ovarian cancer. The Italian Gynecologic Oncology Society, Cagliari, Sardinia, June 1996 171. Berek JS. Molecular and genetic aspects of early ovarian cancer. Guest lecturer. The University of Freiburg, Germany. German Association for Gynecologic Oncology. September 1996. 172. Berek JS. The European School of Oncology. Symposium on Gynecologic Oncology. Radiation therapy for gynecologic malignancy. Budapest, Hungary, September, 1996. 173. Berek JS. Genetics and screening in ovarian cancer. Michigan State University School of Medicine. Guest Lecturer. Grand Rapids, Michigan. September 1996. 174. Berek JS. Endometrial hyperplasia and cancer. Frank R. Lock Lecture. Bowman Gray School of Medicine. Winston-Salem, NC. October 1996. 175. Berek JS. Ovarian cancer. Lock Symposium. Bowman Gray School of Medicine. Winston- Salem, NC. October 1996. 176. Berek JS. Ovarian cancer. Women’s Health Symposium. UCLA School of Medicine, Los Angeles, CA. February 1997 177. Berek JS. Contemporary diagnosis and management of ovarian cancer. San Francisco Gynecological Society, February 1997 178. Berek JS. Ovarian cancer. Endometrial cancer. San Francisco Kaiser Permanente Medical Center. February 1997 179. Berek JS. Molecular biology of ovarian cancer. Stanford University. Grand Rounds. February 1997. 180. Berek JS. BRCA1 and BRCA2 in ovarian and breast cancer. Society of Gynecologic Investigation. Annual Scientific Meeting. San Diego, CA March 1997 59
  • 60. Jonathan S. Berek, MD, MMS 181. Dorigo O, et al, Berek JS, The development of an vaccine using antisense TGF-beta and IL-2 gene therapy. Society of Gynecologic Oncologists. Plenary Session, March 1997. 182. Berek JS, Session chair, Ovarian cancer screening trials. International symposium on Ovarian cancer screening. Royal College of Obstetricians and Gynaecologists, London, England, April 1997. 183. Berek JS, Session chair, Molecular biology and genetics of gynecologic malignancies. Gene therapy of ovarian cancer. Bienniel scientific meeting, European Society of Gynaecological Oncology, Coimbra, Portugal, April 1997. 184. Berek JS. BRCA1 and BRCA2 in ovarian cancer. Management of ovarian cancer. Management of early stage cervical cancer. Postgraduate course. Annual clinical meeting. American College of Obstetricians and Gynecologists, Las Vegas, NV, April 1997. 185. Berek JS. Chair, Gene therapy for ovarian cancer. Sixth Biennial meeting of the Helene Harris Memorial Trust, International symposium on ovarian cancer. Los Angeles, CA, May 1997. 186. Berek JS. Chair, Ovarian cancer symposium. Annual scientific meeting. American Society of Clinical Oncologists. Denver, CO, May 1997. 187. Berek JS. Contemporary diagnosis and management of ovarian carcinoma. John Wayne Cancer Institute, Los Angeles, CA, July 1997. 188. Dorigo O, Young J, Ribas A, Economou J, Berek JS. Efficiency of adenovirus mediated gene delivery into human ovarian cancer cells is significantly reduced in presence of ovarian cancer ascites and in three dimensional culture systems. Presented at the International Gene Therapy Conference - San Diego 1997. 189. Berek JS. Subgroup B: Secondary Therapy - Strategic Planning Conference - New Directions in Ovarian Cancer Research, Washington DC, December 1997. 190. Berek JS. Biology Moderator. Society of Gynecologic Oncologists, Orlando, Florida, February 1998. 191. Berek JS. Oncology Moderator. Society for Gynecologic Investigation, Atlanta, GA, March 1998. 192. Dorigo O, Horton H, Hernandez P, Anderson D, Norman J, Parker S, Berek J. Gene therapy of ovarian cancer using intraperitoneal injection of IL-2 plasmid DNA. Abstract #F168 - Presented at the 45th annual meeting of the Society for Gynecologic Investigation; Atlanta, GA, March 1998. 193. Dorigo O, Young J, Nivatpumin P, Berek JS. Abstract #3499. Inhibition of gene delivery and Wtp53 induced growth arrest in human ovarian cancer cells by ovarian cancer ascites and in three dimensional culture systems. Presented at the American Association for Cancer Research, March 1998. 194. Horton H, Dorigo O, Hernandez P, Anderson D, Berek J, Norman J, Parker S. Abstract #3480. Plasmid-mediated gene therapy of ovarian cancer. Presented at the American Association for Cancer Research, March 1998. 60
  • 61. Jonathan S. Berek, MD, MMS 195. Berek JS. Genetics of ovarian malignancies. CHW Central California 1998 Cancer Symposium - Gynecologic Oncology, Bakersfield, CA - April 1998. 196. Berek JS. Management of ovarian carcinomas. CHW Central California 1998 Cancer Symposium - Gynecologic Oncology, Bakersfield, CA - April 1998. 197. Gregg J, Garban HJ, Berek JS, Bonavida B. cDNA microarrays for gene expression analysis in ovarian cancer. - Presented at the Western Association of Gynecologic Oncologists, May 1998, Napa, California. 198. Garban HJ, Fukuto J, Berek JS, Bonavida B. Interferon-gamma-induced nitric oxide sensitizes the AD10 ovarian carcinoma cell line to TNF-α-mediated cytotoxicity. Presented at the Western Association of Gynecologic Oncologists, May 1998, Napa, California. 199. Dorigo O, Horton H, Hernandez P, Anderson D, Norman J, Parker S. Berek J. Gene therapy of ovarian cancer using intraperitoneal injection of IL-2 plasmid DNA. Presented at the Western Association of Gynecologic Oncologists, May 1998, Napa, California. 200. Berek JS. Endometrial cancer. Meet the Professor. American Society of Clinical Oncology, Los Angeles, May 1998. 201. Berek JS, Markman M, Stonebraker B, Lentz S, Adelson MD, DeGeest K, Moore D. Intraperitoneal alpha-interferon in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group Study. Poster Presentation, 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, May 1998. 202. Berek JS. Contemporary management of epithelial ovarian cancer. American College of Obstetricians and Gynecologists, 46th Annual Clinical Meeting, Postgraduate Course, New Orleans, May 1998. 203. Berek JS. Genetics of ovarian and breast cancer. American College of Obstetricians and Gynecologists, 46th Annual Clinical Meeting, Postgraduate Course, New Orleans, May 1998. 204. Berek JS. Early stage cervical cancer. American College of Obstetricians and Gynecologists, 46th Annual Clinical Meeting, Postgraduate Course, New Orleans, May 1998. 205. Berek JS. The contemporary management of ovarian cancer. University of Utah, June 1998. 206. Berek JS. A patient with a pelvic mass should be operated on only by a gynecologic oncologist at a tertiary care center. Controversies in first-line therapy for ovarian carcinoma-revisited - A Gynecologic Oncology Group Educational Symposium, Toronto, Canada - July 1998. 207. Berek JS. Detection and management of early ovarian malignancy. Shirley Nissen Lectureship, Orange County Obstetrics and Gynecology Society, November 1998. 208. Berek JS. Contemporary management of ovarian cancer. Shirley Nissen Lectureship, University of California at Irvine Medical Center, November 1998. 209. Dorigo O, Young J, Nivatpumin, Chen L-M, Berek JS. Impact of Ovarian Cancer Ascites in the Efficiency of Adenovirus and Liposome Mediated Gene Delivery into Human Ovarian Cancer Cells. Proceedings of the Society of Gynecologic Investigation. Scientific Program and Abstracts, 46th Annual Meeting, March 1999. 61
  • 62. Jonathan S. Berek, MD, MMS 210. Berek JS. Low Stage Ovarian Malignancy: When is Adjuvant Therapy Necessary? Meet the Professor. Proceedings of the Society of Gynecologic Oncologists, 30: March 1999. 211. Peters WA, Liu PY, Barrett R, Gordon W, Stock R, Berek JS, DiSaia PJ, Souhami L, Grigsby P, Alberts DS. Cisplatin, 5-Fluorouracil Plus Radiation Therapy are Superior to Radiation Therapy as Adjunctive Therapy in high-Risk, Early-Stage Carcinoma of the Cervix After radical Hysterectomy and Pelvic Lymphadenectomy: report of a Phase III Inter-Group Study. Proceedings of the Society of Gynecologic Oncologists. 30:1, Abstract 1999. 212. Benjamin I, Alvarez R, Berchuck A, Berek J, Karlan B, Levenback C, Runowicz C, Morris M. Women’s Cancer Network: Analysis of Risk Assessment Survey Responses. Proceedings of the Society of Gynecologic Oncologists. 30:32, 1999. 213. Berek JS Update on clinical trials in ovarian cancer by the Gynecologic Oncology Group. Proceedings of the Sixth Bienneal Meeting of the Helene Harris Memorial Trust Forum on Ovarian Cancer. The Nobel Forum and the Karolinska Institute, Stockholm, Sweden, 6, April,1999 214. Berek JS , Bast RC Summary of screening strategies for ovarian cancer. Proceedings of the Sixth Bienneal Meeting of the Helene Harris Memorial Trust Forum on Ovarian Cancer. The Nobel Forum and the Karolinska Institute, Stockholm, Sweden 6, April, 1999 215. Berek JS. Etiology of ovarian cancer. Postgraduate course in gynecologic oncology. Royal Hospital for Women. Sydney, Australia. April 1999. 216. Berek JS. Pitfalls in the management of cervical cancer. Postgraduate course in gynecologic oncology. Royal Hospital for Women. Sydney, Australia. April 1999. 217. Berek JS. Chair, Gynecologic malignancies. American Society of Clinical Oncologists, Proceedings of the 35th annual meeting. Atlanta, GA, May, 1999. 218. Berek JS. Genetics of ovarian cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Postgraduate course in gynecologic oncology, May 1999. 219. Berek JS. The management of ovarian cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Postgraduate course in gynecologic oncology, May 1999. 220. Berek JS. The treatment of early cervical cancer. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Postgraduate course in gynecologic oncology, May 1999. 221. Berek JS. Molecular biology of gynecologic cancer. Symposium chair. International Gynecological Cancer Society, Rome, Italy, September 1999. 222. Berek JS. The pathophysiology of gynecologic tumors. International Gynecologic Cancer Society. Rome, Italy, September 1999. 223. Berek JS. Continuous infusion topotecan in persistent and recurrent epithelial ovarian cancer. Symposium of second-line chemotherapy. Dallas, TX October 1999. 224. Lentz SE, Zempolich KA, Rodriguez M, Berek JS, Cheng PC, Cliby W, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Robinson WR, Morrow CP, Chi D, Dubeau L. Telomerase 62
  • 63. Jonathan S. Berek, MD, MMS activity in abdominal washings from patients undergoing second-look laparotomy for ovarian carcinoma. Poster Presentation, 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 2000. 225. Gold MA, Walker JL, Berek JS, Hallum AV, Garcia DJ, Alberts DS. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multi-center phase II trial in patients with advanced gynecologic malignancies. Poster Presentation, 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 2000. 226. Berek JS. New strategies in the treatment of recurrent ovarian cancer. SmithKline Beecham Symposium. Los Angeles, CA, March 2000. 227. Berek JS. Treatment of ovarian cancer. Orange County Obstetrical and Gynecologic Congress, 22nd Annual. April 2000. 228. Berek JS. Treatment of endometrial cancer. Orange County Obstetrical and Gynecologic Congress, 22nd Annual. April 2000. 229. Berek JS. Treatment of preinvasive and early cervical cancer. Orange County Obstetrical and Gynecologic Congress, 22nd Annual. April 2000. 230. Berek JS. Management of ovarian cancer. Emory University. Postgraduate Course in Gynecologic Oncology, Sea Island, Georgia, May 2000. 231. Berek JS. Management of early cervical cancer. Emory University. Postgraduate Course in Gynecologic Oncology, Sea Island, Georgia, May 2000. 232. Berek JS. Management of endometrial cancer. Emory University. Postgraduate Course in Gynecologic Oncology, Sea Island, Georgia, May 2000. 233. Berek JS. Contemporary management of ovarian cancer. Brown University. Grand Rounds. Women’s and Infants Hospital of Rhode Island, Providence, RI, May 2000. 234. Berek JS. Gynecologic Malignancies. Chair. American Society of Clinical Oncologists. Annual Clinical Meeting. New Orleans, LA May 2000. 235. Berek JS. The genetics, screening and management of ovarian cancer. Brown University School of Medicine. Providence, RI, may 2000. 236. Berek JS. The management of ovarian cancer. International Federation of Obstetrics and Gynecology (FIGO) International Symposium, Washington, DC, September 2000. 237. Berek JS. The immunotherapy of ovarian cancer with monoclonal antibodies. Conference of immunotherapy in ovarian cancer. Denver, CO, September, 2000. 238. Berek JS. The immunotherapy of ovarian cancer with monoclonal antibodies directed against CA125. Harvard Club, Boston, MA, September 2000. 239. Berek JS. The immunotherapy of ovarian cancer using monoclonal antibodies. International Gynecological Cancer Society Biennual Meeting, Buenos Aires, Argentina, October 2000. 240. Berek JS. The genetics, screening and prevention of ovarian cancer. International Distinguished Lecturer. Clinical Oncology Society of Australia (COSA), Adelaide, Australia, November 2000. 63
  • 64. Jonathan S. Berek, MD, MMS 241. Berek JS. The immunology and immunotherapy of ovarian cancer. International Distinguished Lecturer. Clinical Oncology Society of Australia (COSA), Adelaide, Australia. November 2000. 242. Berek JS. The genetics, detection and prevention of ovarian cancer. Guest Lecturer. The Boston Obstetrics Society, Harvard Club, Boston, MA, February 2001 243. Berek JS. The genetics, detection and prevention of ovarian cancer. Presidential roundtable discussion. Society of Gynecologic Oncologists. Nashville, TN, March 2001 244. Berek JS. Symposium on the management of gynecologic cancer. Society of Gynecologic Oncologists. Nashville, TN, March 2001. 245. Berek JS. Monoclonal antibody therapy in ovarian cancer. Helen Harris Memorial Trust Biennual Meeting, MD Anderson Cancer Center, Houston, TX, March 2001. 246. Berek JS. Communications in medicine: challenging physician-patient interactions and breaking bad news. Obstetrical and Gynecological travel Club, UCLA School of Medicine, Los Angeles, CA, April 2001. 247. Berek JS. Classification of atypical cells of unknown significance. Committee review. Bethesda III Committee, National Cancer Institute, National Institutes of Health, Bethesda, MD, May 2001. 248. Berek JS, Ehlen T, Gordon A, et al. Monocolonal antibody against CA125 (Ovarex) as consolidation in ovarian cancer: a prospective randomized trial. American Society of Clinical Oncologists (ASCO), Annual Meeting, San Francisco, CA, May 2001. 249. Berek JS, Thigpen JT, McGuire W, et al. Symposium on the treatment of ovarian cancer. American Society of Clinical Oncologists (ASCO), Annual Meeting, San Francisco, CA, May 2001. 250. Berek JS. The genetics, detection and prevention of ovarian cancer. Grand rounds. University of North Carolina. Chapel Hill, NC, May 2001. 251. Berek JS. Immunotherapy with monoclonal antibody against CA125 in ovarian cancer. Ovarian Cancer National Alliance, Fourth Annual Advocacy Confernece, Indianapolis, IN, September 2001. 252. Berek JS. Secondary cytoreductive surgery in ovarian cancer. MD Anderson Cancer Center Forum, Houston, TX. September 2001. 253. Gordon A, Berek J, Bloss J, Ehlen T, Nicodemus C. Critical role of circulating CA125 for immune responses and clinical efficacy of Ovarex Mab-B43.13 monoclonal antibody treatment of patients with ovarian cancer. MD Anderson Cancer Center Conference, Houston, TX, September 2001 254. Berek JS. The genetics, detection and prevention of ovarian cancer. Grand Rounds. UCLA School of Medicine, Department of Obstetrics and Gynecology, September 2001. 255. Berek JS. The genetics, detection and prevention of ovarian cancer. Michigan State University School of Medicine, Grand Rounds, Detroit, MI, October 2001. 256. Berek JS. Communications in oncology: challenging physician-patient interactions. Michigan State University School of Medicine, Teaching Rounds, Detroit, MI, October 2001. 64
  • 65. Jonathan S. Berek, MD, MMS 257. Berek JS. The genetics, detection and prevention of ovarian cancer. The Seventeenth Annual Asbury Memorial Lectureship. Oregon State University, Corvallis, OR, November 2001. 258. Berek JS. The management of ovarian cancer. The Seventeenth Annual Asbury Memorial Lectureship. Oregon State University, Corvallis, OR, November 2001. 259. Berek JS. The management of endometrial cancer. The Seventeenth Annual Asbury Memorial Lectureship. Oregon State University, Corvallis, OR, November 2001. 260. Berek JS. Immunotherapy with monoclonal antibody against CA125 in ovarian cancer. The Chemotherapy Foundation of New York. Mount Sinai School of Medicine, New York, NY, November 2001. 261. Berek JS. Surgery for ovarian cancer. International Guest lecturer. Finnish National Oncology Society. Kuopulo, Finland, November 2001. 262. Baum L, Berek JS, Slavin S, Steadman R, Usatine R. A new fourth year structure at UCLA: Colleges. Group on Educational Affairs Annual Meeting, American Association of Medical Colleges, Washington, DC, November 2001. 263. Aguilera P, Baum L, Berek JS, Slavin S, Steadman R, Usatine R. UCLA Colleges: capturing the fourth year. American Association of Medical Colleges, Washington, DC, November 2001. 264. Berek JS. The initial discussion with the oncology patient: informed consent for surgery. On Symposium for Communications in oncology: challenging physician-patient interactions. Berlex Symposium, San Diego, CA, December 2001. 265. Berek JS. Contemporary management of ovarian cancer. Mirian Medical Center, Santa Maria, CA, February 2002. 266. Berek JS. Biologic and immunotherapy of ovarian cancer. Symposium on Molecular Therapeutics, Society of Gynecologic Oncologists, Miami, FL, March 2002. 267. Berek JS. Interferon in the management of ovarian cancer. Symposium on Interferon in ovarian cancer. Society of Gynecologic Oncologists, Miami, FL, March 2002. 268. Ehlen T, Berek JS, Gordon A, Bloss J, Nicodemus C. Critical role of circulating CA125 for immune responses and clinical efficacy of Ovarex Mab-B43.13 monoclonal antibody treatment of patients with ovarian cancer. Society of Gynecologic Oncologists, Miami, FL, March 2002. 269. Berek JS, McGuire W, Armstrong D, Morris P. Management of gynecologic malignancies. Symposium. Society of Gynecologic Oncologists, Miami, FL, March 2002. 270. Berek JS. Contemporary management of ovarian cancer. Distinguished Lecturer, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA, April 2002. 271. Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Muderspach LI, Penson RT, Robinson WR, Rodriquez M, Yu MC, Zempolich K, Dubeau L. Detection of residual, subclinical ovarian carcinoma following completion of adjuvant chemotherapy for ovarian cancer. Proceedings of the American Association for Cancer Research, April 2002. 65
  • 66. Jonathan S. Berek, MD, MMS 272. Berek JS. Screening for common malignancies. Postgraduate Course 060 Symposium Moderator. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Los Angeles, CA, May 2002. 273. Berek JS. General principles of cancer screening. Postgraduate Course 060 Symposium. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Los Angeles, CA, May 2002. 274. Berek JS. Genetics of ovarian cancer. Postgraduate Course 060 Symposium. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Los Angeles, CA, May 2002. 275. Berek JS. Prevention, detection and screening for ovarian cancer. Postgraduate Course 060 Symposium. American College of Obstetricians and Gynecologists, Annual Clinical Meeting, Los Angeles, CA, May 2002. 276. Ehlen TG, Gordon AN, Fingert HJ, Nicodemus CF, Schultes BC, Whiteside TL, Berek JS. Adjuvant treatment with monoclonal antibody OvaRex Mab-B43.13 targeting CA125 induces robust immune responses associated with prolonged time to relapse in a randomized, placebo- controlled study in patients with advanced epithelial ovarian cancer. Abstract 31. Proceedings of the American Society of Clinical Oncologists. Orlando, FL, May 2002. 277. Berek JS. Interferon for ovarian cancer. University of Vermont School of Medicine. Burlington, VT, June 2002. 278. Berek JS. Secondary cytoreductive surgery for ovarian cancer. Third International Conference on Ovarian Cancer. University of Texas MD Anderson Cancer Center. Houston, TX, September 2002. 279. Berek JS. Biologic and immunologic therapy of ovarian cancer. Harvard University, Progress in the management of gynecologic cancer, invited scholar, Cambridge, MA, October 2002. 280. Berek JS. Biologic and immunologic therapy of ovarian cancer. Symposium on molecular techniques in gynecologic cancer. International Gynecological Cancer Society, Seoul, Korea, October 2002. 281. Berek JS. Contemporary management of ovarian cancer. Grand Rounds, Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, December 2002. 282. Berek JS. Clinical and laboratory research/GOG trials: Candidate/fellow career development forum. Society of Gynecologic Oncologists. New Orleans, LA, February 2003. 283. Berek JS. Faculty: Armstrong DK, Coleman R, McGuire W, Sabbatini P. Moderator and presenter: Cases in gynecologic oncology. Society of Gynecologic Oncologists. New Orleans, LA, February 2003. 284. Howe C, Lagasse L, Hacker NF, Berek JS. Pelvic exenteration for recurrent gynecologic malignancy: 45-year experience and analysis of survival by time period and primary site. Society of Gynecologic Oncologists. New Orleans, LA, February 2003, abstract 137. 285. Memarzadeh S, Nastarajan S, Dandade DP, Ostrzega N, Saber PA, Busitttil A, Lentz SE, Berek JS. Lymph-vascular and perineural invasion in the parametria: a surgical and pathologic prognostic factor for early stage cervical cancer. Society of Gynecologic Oncologists. New Orleans, LA, February 2003, abstract 148. 66
  • 67. Jonathan S. Berek, MD, MMS 286. Cass I, Walsh C, Holschneidfer CH, Tieu K, Li AJ, Lagasse LD, Leuchter R, Berek JS, Karlan BY. Co-existing ovarian malignancy in young women with endometrial cancer. Society of Gynecologic Oncologists. New Orleans, LA, February 2003, abstract 136. 287. Berek JS. Genetics, prevention and early detection of ovarian cancer. Department of Pathology. Grand Rounds. David Geffen School of Medicine at UCLA, February 2003. 288. Berek JS. Chemotherapy for recurrent and persistent ovarian cancer. Chemotherapy Symposium. Lo Jolla, CA, February 2003. 289. Berek JS. Chair: Symposium on immunotherapy. Helene Harris Memorial Trust. Ninth biennial international forum on ovarian cancer. Stratford-upon-avon, March 2003. 290. Berek JS. Chemotherapy for recurrent and persistent ovarian cancer. Chemotherapy Symposium. San Francisco, CA, March 2003. 291. Berek JS. Monoclonal antibody therapy for ovarian cancer. Helene Harris Memorial Trust. Ninth biennial international forum on ovarian cancer. Stratford-upon-avon, March 2003. 292. Berek JS. Classification of abnormal cervical cytology and the Bethesda III System. Symposium on the management of cervical intraepithelial neoplasia. American College of Obstetricians and Gynecologists. New Orleans, LA, April 2003 293. Berek JS. Chemotherapy for recurrent and persistent ovarian cancer. Pasadena, CA, May 2003. 294. Berek JS, Taylor PT, Gordon AN, Schultes BC, Whiteside TL, Nicodemus CF. Randomized placebo-controlled study of oregovomab for consolidation of clinical remission in patients with ovarian cancer: prolonged disease-free survival in optimal chemosensitive patients. Proceedings of the American Society of Clinical Oncologists. Abst 660 Chicago, May-June 2003. 295. Fleming GF, Sill MA, Thigpen JT, Adler LM, Berek JS, DiSilvestro PA, Horowitz IR. Phase II evaluation of trastuzamab in patients with advanced or recurrent endometrial carcinoma: a report of Gynecol.ogic Oncology Group protocol 181B. Proceedings of the American Society of Clinical Oncologists. Abst 1821 Chicago, May-June 2003. 296. Berek JS. Chemotherapy for recurrent and persistent ovarian cancer. Los Angeles, CA, June 2003. 297. Berek JS. Gynecologic malignancies. ASCO review. Imedex Coinference. Huntington Beach, CA. June 2003. 298. Berek JS. Chemotherapy for recurrent and persistent ovarian cancer. Spokane, WA, June 2003. 299. Bryan D, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstgruction in advanced ovarian cancer. Proceedings of the Western Association of Gynecologic Oncologists. Steamboat Springs, CO, June 2003. 300. Berek JS. Genomics and cytoreductive surgery in ovarian cancer. Discussant. American Gynecological and Obstetrical Society. Annual Meeting. Napa, CA, September 2003. 301. Berek JS. Immunotherapy of ovarian cancer. Grand Rounds. Department of Obstetrics and Gynecology. David Geffen School of Medicine at UCLA. September 2003. 67
  • 68. Jonathan S. Berek, MD, MMS 302. Berek, JS. Contemporary management of ovarian cancer. Cohen Lecturer. New York State, North Shore University Hospital, New York, October 2003. 303. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent or persistent pelvic malignancy: a 45-year experience. Society of Pelvic Surgeons. Pittsburgh, PA. November 2003. 304. Berek JS. Discussant: Diagnostic efficacy of optical coherence tomography for preinvasive and invasive cancer of the cervix and vulva. Society of Pelvic Surgeons. Pittsburgh, PA. November 2003. 305. Berek JS. Immunotherapy of ovarian cancer. Distinguished Guest Speaker. Norwegian Cancer Society. Oslo, Norway. December 2003. 306. Berek JS, Taylor P, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S,Schultes BC, Whiteside T, Nicodemus CF. Randomized phase II placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Society of Gynecologic Oncologists. San Diego, CA. February 2004. 307. Berek JS. Vaginal reconstruction. Postgraduate Course on Pelvic Surgery. Society of Gynecologic Oncologists. San Diego, CA. February 2004. 308. Berek JS. Chemotherapy for cervical cancer. Symposium of the treatment of gynecologic cancer. Society of Gynecologic Oncologists. San Diego, CA. February 2004. 309. Berek JS. Physician-patient communications. Postgraduate Course on Communcations. Society of Gynecologic Oncologists. San Diego, CA. February 2004. 310. Berek JS, Taylor P, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S,Schultes BC, Whiteside T, Nicodemus CF. Relationship to time to relapse and survival post relapse: exploration of risk factors from the first annual follow-up data set of randomized placebo- controlled study of oregovomab as a consolidation therapy of patients with advanced ovarian cancer. American Society of Clinical Oncologists. New Orleans, LA. June 2004. 311. Berek JS, Taylor P, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S,Schultes BC, Whiteside T, Nicodemus CF. Relationship to time to relapse and survival post relapse: exploration of risk factors from the first annual follow-up data set of randomized placebo- controlled study of oregovomab as a consolidation therapy of patients with advanced ovarian cancer. International Society of Gynecologic Cancer. Edinburgh, UK. October 2004. 312. Berek JS. Discussant. Intraperitoneal immunotherapy with yttrium-labeled anti-mucin monoclonal antibody: randomized prospective clinical trial of consolidation therapy in epithelial ovarian cancer. Soc Gynecol Oncol. Miami, FL, March 2005. 313. Berek JS. Chemotherapy for cervical cancer. Symposium on chemotherapy for gynecologic malignancies. Soc Gynecol Oncol. Miami, FL, March 2005. 314. Berek JS. Discussant. Novel Therapies. International Symposium on Ovarian Cancer. Helene Harris Memorial Trust. Washington, DC. April 2005. 68
  • 69. Jonathan S. Berek, MD, MMS 315. Orr J, Taylor P, Berek JS, Gordon A, Nicodemus CF. Relationship of CA125 to predict outcome: a randomized placebo-controlled study of oregovomab as a consolidation therapy of patients with advanced ovarian cancer. Am Soc Clin Oncol. Orlando, FL, May 2005. 316. Berek JS. Immunotherapy and vaccine development for ovarian cancer. International Society of Gynecologic Cancer. Kyoto, Japan, November 2005. 317. Berek JS. Pelvix exenteration and reconstructive operations for recurrent gynecologic malignancies. International Society of Gynecologic Cancer. Kyoto, Japan, November 2005. 69

×